To see this page, please, enable javaScript and styleSheets on your browser: Tools -> Internet Options ...
Reload !
Gene HGSandMRPL12andSLC25A10TABLE OF CONTENTS / OPEN CLOSE ALL PARAGRAPHS
Summary back to top
Compact gene diagram back to top
678 representative clones for gene HGSandMRPL12andSLC25A10 back to top
cDNA accession
Links to the sequence
Tissue

most 5' clones
in red
Match
mRNA
From bp
to bp
in mRNA
From bp
to bp
in accs.
Clone encodes
complete protein
(with AA variation)
Features Anomalies
detected by
AceView
Accession
match over
(% length)
Base differences
relative to genome
(% identity)
DR001213 fetal brain .a 1 to 752 1 to 754   tiling clone,   754/821
(91 %)
7 diff
(99.2 %id)
DC415262 trachea .a 34 to 577 1 to 544       544/544
(100 %)
0 diff
(100 %id)
BG771530 testis .a 47 to 824 1 to 772       772/774
(99 %)
13 diff
(98.4 %id)
BC003565 Skin, melanotic melanoma. .a 59 to 2966 1 to 2908 exact tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 2908/2908
(100 %)
0 diff
(100 %id)
AL520159 brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized .a 59 to 1012 1 to 950       950/974
(97 %)
11 diff
(98.9 %id)
NM_004712.3   .a 59 to 2966 1 to 2908 exact RefSeq, AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 2908/2908
(100 %)
0 diff
(100 %id)
U43895   .a 61 to 2966 1 to 2906 exact     2906/2906
(100 %)
3 diff
(99.9 %id)
BX417041 placenta .a 65 to 1069 1 to 1001       1001/1001
(100 %)
12 diff
(98.9 %id)
BM544364 brain, hippocampus .a 65 to 1069 1 to 1000       1000/1011
(98 %)
18 diff
(98.3 %id)
DA439476 tongue, tumor tissue .a 70 to 617 2 to 549   capped   548/548
(100 %)
0 diff
(100 %id)
BF206188 brain, neuroblastoma .a 72 to 829 1 to 756       756/759
(99 %)
22 diff
(97.2 %id)
BM803393 leiomyosarcoma, uterus .a 72 to 924 43 to 903       859/1100
(78 %)
31 diff
(97.2 %id)
CO247729 Chondrosarcoma Lung Metastasis cell lines, lung .a 73 to 757 8 to 684       677/826
(81 %)
14 diff
(98.4 %id)
D84064 placenta .a 76 to 2970 1 to 2895 exact     2895/2896
(99 %)
1 diff
(100.0 %id)
BG752024 eye, normal pigmented retinal epithelium .a 76 to 876 1 to 801       801/807
(99 %)
9 diff
(98.9 %id)
BE408682 choriocarcinoma, placenta .a 77 to 742 1 to 664       664/665
(99 %)
5 diff
(99.3 %id)
BG771588 testis .a 80 to 776 1 to 698       698/700
(99 %)
10 diff
(98.6 %id)
BG034612 breast, mammary adenocarcinoma, cell line .a 83 to 875 1 to 790       790/801
(98 %)
18 diff
(97.8 %id)
DB187409 liver, tumor tissue .a 86 to 652 2 to 568   capped   567/567
(100 %)
0 diff
(100 %id)
AL560151 B cells (Ramos cell line), B cells from Burkitt lymphoma .a 87 to 1066 1 to 974       974/974
(100 %)
7 diff
(99.3 %id)
CR977546 T-Lymphocytes .a 87 to 744 1 to 658       658/658
(100 %)
0 diff
(100 %id)
BI257534 cervical carcinoma cell line, cervix .a 90 to 868 1 to 790       790/806
(98 %)
38 diff
(95.3 %id)
BI460684 testis .a 90 to 821 1 to 732       732/735
(99 %)
11 diff
(98.6 %id)
BQ425577 melanotic melanoma, skin .a 92 to 945 1 to 861       861/887
(97 %)
10 diff
(98.9 %id)
CV574994 cornea, eye .a 93 to 728 1 to 636       636/636
(100 %)
0 diff
(100 %id)
AL539358 brain, fetal brain .a 94 to 1097 1 to 999       999/1006
(99 %)
10 diff
(99.1 %id)
DB451584 testis .a 95 to 588 1 to 494       494/494
(100 %)
0 diff
(100 %id)
CB995706 placenta, pre-eclamptic placenta .a 95 to 865 28 to 803       776/825
(94 %)
18 diff
(97.9 %id)
CB995431 placenta, pre-eclamptic placenta .a 95 to 877 29 to 818       790/830
(95 %)
28 diff
(96.7 %id)
CB997322 placenta, pre-eclamptic placenta .a 95 to 874 28 to 809       782/809
(96 %)
10 diff
(98.8 %id)
CB996069 placenta, pre-eclamptic placenta .a 95 to 744 28 to 685       658/822
(80 %)
17 diff
(98.0 %id)
BX416374 neuroblastoma .a 96 to 876 1 to 780       780/810
(96 %)
7 diff
(99.2 %id)
BG393744 embryonal carcinoma, cell line, testis .a 96 to 876 1 to 779       779/786
(99 %)
13 diff
(98.4 %id)
AL538187 brain, fetal brain .a 97 to 1071 1 to 973       973/973
(100 %)
6 diff
(99.4 %id)
BU846474 ovary, teratocarcinoma, cell line .a 99 to 913 1 to 818       818/950
(86 %)
6 diff
(99.4 %id)
BU553847 ovary, teratocarcinoma, cell line .a 99 to 979 1 to 882       882/913
(96 %)
17 diff
(98.2 %id)
BU557008 ovary, teratocarcinoma, cell line .a 99 to 973 1 to 885       885/951
(93 %)
17 diff
(98.3 %id)
BU850155 ovary, teratocarcinoma, cell line .a 99 to 1012 1 to 918       918/920
(99 %)
14 diff
(98.5 %id)
BE302494 melanotic melanoma, skin .a 100 to 713 1 to 614       614/614
(100 %)
0 diff
(100 %id)
CN482479 eye .a 101 to 733 1 to 633       633/633
(100 %)
0 diff
(100 %id)
BG421599 Kidney, renal cell adenocarcinoma .a 104 to 883 1 to 783       780/987
(79 %)
24 diff
(97.6 %id)
BG753478 eye, normal pigmented retinal epithelium .a 104 to 814 1 to 712       712/712
(100 %)
6 diff
(99.2 %id)
BM922414 leukocyte .a 104 to 973 14 to 890       877/1162
(75 %)
29 diff
(97.6 %id)
CD675019 eye, lens .a 105 to 365 1 to 261       261/261
(100 %)
0 diff
(100 %id)
BM803438 leiomyosarcoma, uterus .a 105 to 772 1 to 672       672/1155
(58 %)
16 diff
(98.7 %id)
AL583523 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .a 106 to 1071 1 to 965       965/1098
(87 %)
4 diff
(99.7 %id)
BG333008 large cell carcinoma, lung .a 106 to 802 1 to 699       699/738
(94 %)
9 diff
(98.8 %id)
BG748492 eye, normal pigmented retinal epithelium .a 106 to 811 1 to 706       706/706
(100 %)
1 diff
(99.9 %id)
BI827274 brain, medulla .a 109 to 810 1 to 701       701/701
(100 %)
3 diff
(99.6 %id)
TI_57174812   .a 109 to 810 31 to 731       701/731
(95 %)
9 diff
(98.8 %id)
BM906354 ovary (pool of 3) .a 120 to 876 1 to 762       762/1066
(71 %)
15 diff
(98.6 %id)
BI461948 testis .a 122 to 878 1 to 758       758/766
(98 %)
10 diff
(98.7 %id)
AL042772 testis .a 123 to 839 1 to 719       719/719
(100 %)
8 diff
(98.9 %id)
TI_1948142498   .a 130 to 979 120 to 970       851/1200
(70 %)
29 diff
(97.6 %id)
BU154884 melanotic melanoma, skin .a 131 to 965 1 to 841       841/890
(94 %)
16 diff
(98.3 %id)
BT009754   .a 136 to 2467 1 to 2332       2332/2334
(99 %)
1 diff
(100.0 %id)
BX338889 Placenta Cot 25-normalized .a 136 to 1066 1 to 928       928/932
(99 %)
5 diff
(99.5 %id)
BM459738 leiomyosarcoma, uterus .a 141 to 965 1 to 826       826/914
(90 %)
9 diff
(99.1 %id)
BG913673 anaplastic oligodendroglioma with 1p/19qloss, brain .a 145 to 876 1 to 735       733/756
(96 %)
15 diff
(98.1 %id)
CN349799 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .a 149 to 840 1 to 692       692/692
(100 %)
0 diff
(100 %id)
AL560305 B cells (Ramos cell line), B cells from Burkitt lymphoma .a 152 to 1066 59 to 970       912/974
(93 %)
10 diff
(99.0 %id)
BG479255 choriocarcinoma, placenta .a 152 to 840 1 to 682       682/682
(100 %)
11 diff
(98.4 %id)
BG479341 choriocarcinoma, placenta .a 152 to 838 1 to 688       688/688
(100 %)
1 diff
(99.9 %id)
CN349795 embryonic stem cells, DMSO-treated H9 cellline .a 167 to 885 13 to 731       719/731
(98 %)
7 diff
(99.1 %id)
BE900288 choriocarcinoma, placenta .a 172 to 867 1 to 690       690/732
(94 %)
12 diff
(98.4 %id)
BM050640 eye, normal pigmented retinal epithelium .a 185 to 873 1 to 687       687/778
(88 %)
20 diff
(97.5 %id)
BU149087 eye, normal pigmented retinal epithelium .a 189 to 1042 1 to 855       855/855
(100 %)
9 diff
(99.0 %id)
CD619202   .a 230 to 1004 8 to 783       776/785
(98 %)
20 diff
(97.5 %id)
TI_57229380   .a 277 to 1043 89 to 853       765/765
(100 %)
14 diff
(98.2 %id)
BI870055 adenocarcinoma, cell line, Liver .a 278 to 1043 1 to 764       764/764
(100 %)
14 diff
(98.2 %id)
BF206164 brain, neuroblastoma .a 291 to 979 1 to 690       690/1026
(67 %)
12 diff
(98.9 %id)
BF314520 brain, neuroblastoma .a 291 to 965 1 to 675       675/680
(99 %)
8 diff
(98.9 %id)
BF525948 brain, glioblastoma with EGFR amplification .a 294 to 1042 1 to 746       746/771
(96 %)
11 diff
(98.6 %id)
BG419029 Kidney, renal cell adenocarcinoma .a 358 to 1071 1 to 705       707/899
(78 %)
22 diff
(97.6 %id)
BE905646 epithelioid carcinoma, Pancreas .a 367 to 1071 1 to 700       700/814
(85 %)
12 diff
(98.6 %id)
CF995726 mixed .a 411 to 1206 8 to 803       796/803
(99 %)
6 diff
(99.3 %id)
BM559316 amelanotic melanoma, cell line, skin .a 423 to 1315 1 to 902       902/1008
(89 %)
10 diff
(99.1 %id)
BM811470 amelanotic melanoma, cell line, skin .a 424 to 1252 1 to 842       842/1054
(79 %)
34 diff
(96.8 %id)
BM911608 amelanotic melanoma, cell line, skin .a 424 to 1226 1 to 811       809/1094
(73 %)
37 diff
(96.7 %id)
BM807963 amelanotic melanoma, cell line, skin .a 424 to 1252 1 to 832       832/1071
(77 %)
13 diff
(98.8 %id)
BM913481 amelanotic melanoma, cell line, skin .a 424 to 1314 1 to 897       895/1017
(88 %)
17 diff
(98.4 %id)
BM423720 amelanotic melanoma, cell line, skin .a 425 to 1369 30 to 983       952/1011
(94 %)
30 diff
(97.1 %id)
BQ718416 sympathetic trunk .a 467 to 1253 1 to 789       789/922
(85 %)
13 diff
(98.6 %id)
BG675963 skin, squamous cell carcinoma .a 480 to 1238 1 to 765       765/767
(99 %)
15 diff
(98.1 %id)
BQ223776 melanotic melanoma, skin .a 516 to 1249 1 to 736       736/846
(86 %)
3 diff
(99.7 %id)
CN349792 embryonic stem cells, DMSO-treated H9 cellline .a 574 to 1226 1 to 653       653/653
(100 %)
0 diff
(100 %id)
BG751671 eye, normal pigmented retinal epithelium .a 599 to 1344 1 to 750       750/752
(99 %)
12 diff
(98.5 %id)
BM047844 carcinoma, cell line, Prostate .a 624 to 1319 1 to 696       696/696
(100 %)
8 diff
(98.9 %id)
CF780905 Pooled Chondrosarcoma Tumor cells .a 702 to 1389 1 to 696       696/1024
(67 %)
19 diff
(98.2 %id)
BG029488 breast, mammary adenocarcinoma, cell line .a 726 to 1509 13 to 796       784/961
(81 %)
30 diff
(96.9 %id)
BU955901 adenocarcinoma, cell line, breast .a 758 to 1585 1 to 830       830/928
(89 %)
8 diff
(99.2 %id)
CA455421 adenocarcinoma, cell line, breast .a 758 to 1528 1 to 774       774/848
(91 %)
5 diff
(99.5 %id)
AI902590 breast .a 806 to 967 162 to 1       162/162
(100 %)
0 diff
(100 %id)
BG341956 B-cells, primary B-cells from tonsils (cell line) .a 846 to 1636 1 to 791       791/1150
(68 %)
34 diff
(97.1 %id)
CF132388 Chondrosarcoma Lung Metastasis cell lines, lung .a 867 to 1618 1 to 751       751/751
(100 %)
8 diff
(99.0 %id)
TI_159676634   .a 867 to 1693 50 to 868       819/1016
(80 %)
18 diff
(98.3 %id)
CR996823 T-Lymphocytes .a 898 to 1689 1 to 797       797/798
(99 %)
5 diff
(99.4 %id)
BG165832 hypernephroma, cell line, Kidney .a 927 to 1694 1 to 770       770/1033
(74 %)
26 diff
(97.5 %id)
TI_59388434   .a 952 to 1737 94 to 879       786/793
(99 %)
11 diff
(98.7 %id)
BM017857 astrocytoma grade IV, cell line, brain .a 955 to 1737 1 to 783       783/790
(99 %)
11 diff
(98.7 %id)
BG423374 Kidney, renal cell adenocarcinoma .a 961 to 1630 1 to 671       671/671
(100 %)
2 diff
(99.8 %id)
BG420071 Kidney, renal cell adenocarcinoma .a 961 to 1699 1 to 738       738/1110
(66 %)
6 diff
(99.5 %id)
CX763369 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .a 972 to 1707 1 to 736     Submitted on the opposite strand 736/736
(100 %)
1 diff
(99.9 %id)
BF797117 lymph, lymphoma, cell line .a 973 to 1699 1 to 728       726/1034
(70 %)
17 diff
(98.4 %id)
BI253588 cervical carcinoma cell line, cervix .a 978 to 1702 1 to 728       728/959
(75 %)
12 diff
(98.8 %id)
AI902591 breast .a 980 to 1049 70 to 1       70/70
(100 %)
0 diff
(100 %id)
BG770401 melanotic melanoma, high MDR (cell line), skin .a 1021 to 1880 1 to 859       861/859
(100 %)
18 diff
(98.0 %id)
BG769607 melanotic melanoma, high MDR (cell line), skin .a 1021 to 1831 1 to 815       815/967
(84 %)
21 diff
(97.9 %id)
BX376146 Neuroblastoma Cot 25-normalized .a 1045 to 2013 1 to 958       958/1026
(93 %)
20 diff
(98.1 %id)
BX391886   .a 1072 to 1987 914 to 1     Submitted on the opposite strand 917/919
(99 %)
16 diff
(98.3 %id)
AL045907 testis .a 1109 to 1594 1 to 486       486/486
(100 %)
0 diff
(100 %id)
BE909236 epithelioid carcinoma, Pancreas .a 1164 to 1837 1 to 676       676/930
(72 %)
17 diff
(98.2 %id)
BI767156 pooled lung and spleen .a 1182 to 2079 1 to 899       899/899
(100 %)
20 diff
(97.8 %id)
TI_57183605   .a 1182 to 2079 36 to 934       899/934
(96 %)
26 diff
(97.3 %id)
BM921449 pooled brain, lung, testis .a 1199 to 2150 13 to 971       959/1042
(92 %)
30 diff
(97.2 %id)
BM552321 astrocytoma grade IV, cell line, brain .a 1203 to 2113 1 to 917       917/1006
(91 %)
18 diff
(98.3 %id)
BM463921 melanotic melanoma, skin .a 1226 to 2187 1 to 962       962/1120
(85 %)
24 diff
(97.9 %id)
BG248338 adenocarcinoma cell line, colon .a 1229 to 1996 1 to 761       761/915
(83 %)
14 diff
(98.5 %id)
BE314706 brain, neuroblastoma .a 1278 to 1957 1 to 678       678/741
(91 %)
15 diff
(98.0 %id)
BF312853 brain, neuroblastoma .a 1281 to 1975 1 to 686       686/774
(88 %)
14 diff
(98.2 %id)
BF312102 brain, neuroblastoma .a 1281 to 2085 1 to 793       793/835
(94 %)
18 diff
(97.9 %id)
BI858050 breast, mammary adenocarcinoma, cell line .a 1303 to 2137 1 to 831       831/832
(99 %)
17 diff
(98.0 %id)
TI_57187806   .a 1303 to 2137 57 to 887       831/832
(99 %)
17 diff
(98.0 %id)
AL558435 T cells from T cell leukemia .a 1351 to 2188 1 to 832       832/907
(91 %)
15 diff
(98.4 %id)
BX344426   .a 1351 to 2184 1 to 836       836/836
(100 %)
4 diff
(99.6 %id)
CN349797 embryonic stem cells, cell lines H1, H7, andH9 .a 1358 to 2064 1 to 716       716/716
(100 %)
7 diff
(99.1 %id)
BG287685 bladder, transitional cell papilloma, cell line .a 1372 to 2096 1 to 719       719/805
(89 %)
9 diff
(98.9 %id)
BG481224 choriocarcinoma, placenta .a 1377 to 2136 1 to 756       756/756
(100 %)
8 diff
(99.0 %id)
BG340660 B-cells, primary B-cells from tonsils (cell line) .a 1428 to 2099 1 to 666       666/805
(82 %)
12 diff
(98.6 %id)
BM556068 amelanotic melanoma, cell line, skin .a 1456 to 2364 1 to 926       924/1159
(79 %)
32 diff
(97.3 %id)
BM810168 amelanotic melanoma, cell line, skin .a 1457 to 2449 1 to 1001       1001/1049
(95 %)
12 diff
(98.9 %id)
CN349803 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .a 1469 to 2182 1 to 718       718/718
(100 %)
2 diff
(99.8 %id)
BI114717 muscle, rhabdomyosarcoma .a 1543 to 2459 1 to 921       921/1041
(88 %)
26 diff
(97.6 %id)
CR978288 T-Lymphocytes .a 1603 to 2318 1 to 717       717/722
(99 %)
2 diff
(99.8 %id)
BM449481 eye, retinoblastoma .a 1623 to 2562 1 to 944       944/1019
(92 %)
14 diff
(98.7 %id)
BI222755 cervical carcinoma cell line, cervix .a 1645 to 2405 1 to 760       760/760
(100 %)
6 diff
(99.3 %id)
AW250714 lung, small cell carcinoma .a 1686 to 2287 2 to 603     Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 602/603
(99 %)
7 diff
(98.9 %id)
BU839514 hepatocellular carcinoma, cell line, Liver .a 1699 to 2539 17 to 871       855/949
(90 %)
49 diff
(94.9 %id)
TI_1948142499   .a 1720 to 2473 880 to 123       758/1253
(60 %)
26 diff
(98.0 %id)
BQ674852 epidermoid carcinoma, cell line, salivary gland .a 1753 to 2528 1 to 779       779/932
(83 %)
18 diff
(98.1 %id)
BF529650 anaplastic oligodendroglioma with 1p/19qloss, brain .a 1762 to 2377 1 to 616       616/616
(100 %)
0 diff
(100 %id)
BG674011 skin .a 1769 to 2593 1 to 825       825/825
(100 %)
1 diff
(99.9 %id)
CD672786 eye, Iris .a 1791 to 2329 1 to 539       539/539
(100 %)
0 diff
(100 %id)
BM823438 Ascites, stomach .a 1794 to 2402 1 to 609       609/609
(100 %)
0 diff
(100 %id)
BQ931916 sciatic nerve .a 1806 to 2660 3 to 860       858/862
(99 %)
23 diff
(97.4 %id)
AL528461 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .a 1840 to 2890 1077 to 41       1037/1077
(96 %)
17 diff
(98.5 %id)
AL539357 brain, fetal brain .a 1862 to 2940 1069 to 8       1062/1074
(98 %)
25 diff
(97.7 %id)
AL581775 B cells (Ramos cell line), B cells from Burkitt lymphoma .a 1862 to 2925 1051 to 1       1051/1067
(98 %)
32 diff
(97.1 %id)
BQ277690 ovary, teratocarcinoma, cell line .a 1873 to 2810 1 to 944       944/1049
(89 %)
13 diff
(98.8 %id)
BQ896874 melanotic melanoma, cell line, skin .a 1873 to 2731 1 to 866       866/866
(100 %)
7 diff
(99.2 %id)
BQ878046 melanotic melanoma, cell line, skin .a 1873 to 2634 1 to 768       768/902
(85 %)
11 diff
(98.8 %id)
AL581646 B cells (Ramos cell line), B cells from Burkitt lymphoma .a 1889 to 2888 989 to 1       989/989
(100 %)
22 diff
(97.8 %id)
BG761472 melanotic melanoma, high MDR (cell line), skin .a 1893 to 2730 1 to 839       839/839
(100 %)
14 diff
(98.4 %id)
BG767164 melanotic melanoma, high MDR (cell line), skin .a 1893 to 2599 1 to 710       710/825
(86 %)
10 diff
(98.8 %id)
AL567185 brain, fetal brain .a 2017 to 2939 920 to 4       917/1002
(91 %)
8 diff
(99.3 %id)
AL561858 brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized .a 2018 to 2939 909 to 1       909/1024
(88 %)
15 diff
(98.6 %id)
AL580258 T cells from T cell leukemia .a 2019 to 2889 882 to 12       871/882
(98 %)
15 diff
(98.3 %id)
BX398818 Placenta Cot 25-normalized .a 2021 to 2917 913 to 30     Submitted on the opposite strand 884/968
(91 %)
19 diff
(98.1 %id)
BI766022 pooled colon, kidney, stomach .a 2023 to 2905 29 to 916       888/940
(94 %)
30 diff
(96.9 %id)
TI_57149898   .a 2023 to 2905 29 to 916       888/940
(94 %)
30 diff
(96.9 %id)
BX376145 Neuroblastoma Cot 25-normalized .a 2043 to 2919 864 to 1       864/864
(100 %)
23 diff
(97.4 %id)
BX344425   .a 2060 to 2938 873 to 1       873/873
(100 %)
12 diff
(98.7 %id)
TI_149313272   .a 2076 to 2966 963 to 85   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 879/958
(91 %)
21 diff
(97.9 %id)
TI_149315532   .a 2076 to 2971 969 to 81   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 889/989
(89 %)
18 diff
(98.2 %id)
TI_153963399   .a 2142 to 2932 77 to 860       784/984
(79 %)
14 diff
(98.6 %id)
TI_149301507   .a 2149 to 2971 889 to 64   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 826/946
(87 %)
10 diff
(99.0 %id)
TI_149299881   .a 2153 to 2966 892 to 86   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 807/956
(84 %)
14 diff
(98.6 %id)
TI_149301870   .a 2158 to 2966 862 to 61   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 802/972
(82 %)
21 diff
(97.9 %id)
CA426504 cell lines, Chondrosarcoma .a 2208 to 2971 781 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 763/766
(99 %)
5 diff
(99.4 %id)
CA442381 Fibrosarcoma .a 2227 to 2966 755 to 17   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 739/743
(99 %)
2 diff
(99.8 %id)
BM666712 eye, human retina .a 2261 to 2969 724 to 15   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 710/710
(100 %)
11 diff
(98.5 %id)
AI417306 anaplastic oligodendroglioma, brain .a 2264 to 2972 706 to 1       706/725
(97 %)
21 diff
(97.2 %id)
AI440346 B-cell, chronic lymphotic leukemia .a 2269 to 2972 704 to 1       704/713
(98 %)
15 diff
(97.9 %id)
BU684969 lung, Primary Lung Cystic Fibrosis EpithelialCells .a 2275 to 2966 709 to 17   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 693/693
(100 %)
2 diff
(99.8 %id)
BQ045406 lung, Primary Lung Cystic Fibrosis EpithelialCells .a 2275 to 2971 718 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 700/700
(100 %)
3 diff
(99.6 %id)
CB850563 lung, Primary Lung Cystic Fibrosis EpithelialCells .a 2276 to 2971 719 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 701/701
(100 %)
5 diff
(99.3 %id)
CA308809 Alveolar Macrophage, lung .a 2277 to 2966 704 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 686/686
(100 %)
4 diff
(99.5 %id)
BM999441 Fibrosarcoma .a 2283 to 2971 709 to 18   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 692/692
(100 %)
7 diff
(99.0 %id)
BQ575979 Chondrosarcoma Grade II, Left Pelvis .a 2285 to 2971 706 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 688/688
(100 %)
1 diff
(99.9 %id)
CA431283 cell lines, Enchondroma .a 2285 to 2971 700 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 682/682
(100 %)
5 diff
(99.3 %id)
CN349800 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 2289 to 2939 1 to 651       651/651
(100 %)
0 diff
(100 %id)
AI553738 anaplastic oligodendroglioma, brain .a 2290 to 2964 691 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 673/673
(100 %)
10 diff
(98.6 %id)
BI819266 pooled brain, lung, testis .a 2310 to 2959 1 to 650       650/836
(77 %)
2 diff
(99.8 %id)
BU625495 cell lines, Enchondroma .a 2311 to 2970 679 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 661/661
(100 %)
2 diff
(99.7 %id)
BG032422 breast, mammary adenocarcinoma, cell line .a 2332 to 2972 1 to 643       643/681
(94 %)
4 diff
(99.5 %id)
CN349802 embryonic stem cells, cell lines H1, H7, andH9 .a 2512 to 2688 1 to 177       177/177
(100 %)
0 diff
(100 %id)
CD107255 brain, Pituitary .a 2517 to 2971 1 to 455   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 455/455
(100 %)
0 diff
(100 %id)
AI499854 anaplastic oligodendroglioma, brain .a 2539 to 2966 428 to 1       428/428
(100 %)
0 diff
(100 %id)
BQ434038 melanotic melanoma, skin .a 2550 to 2971 1 to 422   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 422/422
(100 %)
0 diff
(100 %id)
AW246859 lung, small cell carcinoma .a 2555 to 2971 427 to 11   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 417/417
(100 %)
5 diff
(98.9 %id)
BE312510 brain, neuroblastoma .a 2593 to 2971 1 to 379   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 379/379
(100 %)
0 diff
(100 %id)
AI362004 brain, glioblastoma (pooled) .a 2594 to 2966 373 to 1       373/373
(100 %)
0 diff
(100 %id)
AW590079 pooled germ cell tumors .a 2598 to 2969 372 to 1       372/372
(100 %)
0 diff
(100 %id)
BG055782 anaplastic oligodendroglioma, brain .a 2602 to 2967 366 to 1       366/366
(100 %)
0 diff
(100 %id)
AW137926   .a 2610 to 2966 372 to 16   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 357/357
(100 %)
0 diff
(100 %id)
AI333275 lung .a 2628 to 2971 344 to 1       344/344
(100 %)
0 diff
(100 %id)
AI888921 poorly differentiated adenocarcinoma withsignet ring cell features, stomach .a 2698 to 2966 269 to 1       269/269
(100 %)
0 diff
(100 %id)
AI870114 serous papillary carcinoma, high grade, 2pooled tumors, uterus .a 2811 to 2967 157 to 1       157/157
(100 %)
0 diff
(100 %id)
AW083654 esophagus, squamous cell carcinoma .a 2903 to 2971 84 to 16   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 69/69
(100 %)
0 diff
(100 %id)
AA705635 heart .a 2909 to 2967 59 to 1       59/59
(100 %)
0 diff
(100 %id)
AK297076 cord Blood .b 1 to 1925 2 to 1926 exact tiling clone,   1926/1926
(100 %)
7 diff
(99.7 %id)
BM822917 stomach .b 725 to 1076 1 to 353       353/353
(100 %)
2 diff
(99.5 %id)
BF808967 colon_ins .b 746 to 1166 1 to 421   tiling clone,   421/421
(100 %)
5 diff
(98.9 %id)
BF932484 nervous_tumor .b 769 to 1236 1 to 469       469/469
(100 %)
14 diff
(97.1 %id)
BF935976 nervous_tumor .b 792 to 1212 1 to 421       421/421
(100 %)
2 diff
(99.6 %id)
BM917883 blood, natural killer cells, cell line .b 794 to 1227 1 to 434       434/1167
(37 %)
2 diff
(99.9 %id)
EC471114 Prostate .b 877 to 980 110 to 7       104/110
(94 %)
0 diff
(100 %id)
EC442382 Prostate .b 882 to 980 105 to 9       99/109
(90 %)
0 diff
(100 %id)
BU521866 leiomyosarcoma, uterus .b 892 to 1580 1 to 693       693/883
(78 %)
9 diff
(99.0 %id)
BG389840 embryonal carcinoma, cell line, testis .b 921 to 1594 1 to 670       670/675
(99 %)
10 diff
(98.6 %id)
BM820169 stomach .b 975 to 1144 1 to 169       169/169
(100 %)
1 diff
(99.5 %id)
AW753797 colon .b 977 to 1351 375 to 1       375/391
(95 %)
4 diff
(99.0 %id)
CF144637 CNCAP(3)T-225 cell line, Prostate .b 982 to 1344 8 to 370       363/370
(98 %)
7 diff
(98.2 %id)
TI_154176752   .b 982 to 1550 80 to 647       568/570
(99 %)
11 diff
(98.1 %id)
BG982324 colon_normal .b 1058 to 1518 471 to 14       458/471
(97 %)
3 diff
(99.4 %id)
TI_154186159   .b 1061 to 1629 234 to 800       567/975
(58 %)
64 diff
(93.5 %id)
BM806364 melanotic melanoma, skin .b 1062 to 1647 1 to 592       592/920
(64 %)
20 diff
(97.9 %id)
BE272036 adenocarcinoma cell line, ovary .b 1067 to 1572 1 to 506       506/506
(100 %)
0 diff
(100 %id)
BG987260 head_neck .b 1073 to 1606 1 to 532       532/554
(96 %)
18 diff
(96.8 %id)
BG982120 colon_normal .b 1099 to 1505 407 to 1       407/407
(100 %)
4 diff
(99.1 %id)
CN304706 embryonic stem cells, DMSO-treated H9 cellline .b 1356 to 1730 1 to 376       376/376
(100 %)
7 diff
(98.2 %id)
BM556077 duodenal adenocarcinoma, cell line, small intestine .b 1362 to 2064 1 to 703       703/1053
(66 %)
37 diff
(96.5 %id)
BM811043 amelanotic melanoma, cell line, skin .b 1376 to 2247 11 to 894       884/1087
(81 %)
27 diff
(97.6 %id)
BX463988 brain, fetal brain .b 1383 to 2366 980 to 1       980/980
(100 %)
12 diff
(98.8 %id)
BE939885 uterus_tumor .b 1400 to 1660 270 to 11       260/273
(95 %)
0 diff
(100 %id)
BM020123 astrocytoma grade IV, cell line, brain .b 1408 to 2040 1 to 632       632/632
(100 %)
6 diff
(99.1 %id)
TI_59390903   .b 1409 to 2040 94 to 724       631/631
(100 %)
5 diff
(99.3 %id)
BM843102 lymph node, stomach .b 1418 to 1729 1 to 312       312/312
(100 %)
1 diff
(99.7 %id)
BM851347 lymph node, stomach .b 1418 to 1874 1 to 457       457/457
(100 %)
0 diff
(100 %id)
H24858 breast .b 1420 to 1664 1 to 243       243/243
(100 %)
3 diff
(98.8 %id)
TI_57146192   .b 1478 to 2398 60 to 983   AAA   924/1014
(91 %)
23 diff
(97.8 %id)
BI759050 pooled colon, kidney, stomach .b 1482 to 2398 1 to 920       920/960
(95 %)
22 diff
(97.8 %id)
AL524563 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .b 1494 to 2398 1 to 905       905/905
(100 %)
3 diff
(99.7 %id)
BM790770 stomach .b 1497 to 2028 1 to 532       532/532
(100 %)
1 diff
(99.9 %id)
BM854297 stomach .b 1497 to 1941 1 to 446       446/446
(100 %)
2 diff
(99.6 %id)
BQ083073 stomach .b 1497 to 1968 1 to 472       472/472
(100 %)
2 diff
(99.6 %id)
BM829999 stomach .b 1497 to 2040 1 to 544       544/544
(100 %)
1 diff
(99.9 %id)
BG251707 adenocarcinoma, cell line, Liver .b 1514 to 2213 1 to 699       699/699
(100 %)
7 diff
(99.0 %id)
CB047439 Kidney .b 1518 to 2080 4 to 566   tiling clone, fully sequenced, Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 563/566
(99 %)
5 diff
(99.2 %id)
BE613008 adenocarcinoma, ovary .b 1556 to 1957 1 to 403   fully sequenced,   403/403
(100 %)
2 diff
(99.6 %id)
BM795489 stomach .b 1609 to 2028 1 to 420       420/420
(100 %)
2 diff
(99.6 %id)
BX435225 brain, fetal brain .b 1612 to 2370 761 to 1       761/814
(93 %)
29 diff
(96.5 %id)
BX456010 T cells (Jurkat cell line) .b 1677 to 2387 712 to 1       712/904
(78 %)
13 diff
(98.6 %id)
BU858049 adenocarcinoma, cell line, breast .b 1690 to 2398 1 to 711       711/718
(99 %)
6 diff
(99.2 %id)
BE790419 large cell carcinoma, lung .b 1702 to 2396 1 to 696   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 696/696
(100 %)
10 diff
(98.6 %id)
CA431385 cell lines, Enchondroma .b 1731 to 2396 684 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 666/666
(100 %)
2 diff
(99.7 %id)
BM129770 Islets of Langerhans, Pancreas .b 1735 to 2219 1 to 485   fully sequenced,   485/485
(100 %)
3 diff
(99.4 %id)
EC491193 Prostate .b 1742 to 1846 103 to 1       103/103
(100 %)
2 diff
(98.1 %id)
BM126548 Islets of Langerhans, Pancreas .b 1751 to 2200 1 to 449   fully sequenced,   449/449
(100 %)
3 diff
(99.4 %id)
BM129729 Islets of Langerhans, Pancreas .b 1751 to 2191 1 to 441   fully sequenced, Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 441/441
(100 %)
0 diff
(100 %id)
BU621327 cell lines, Chondrosarcoma .b 1774 to 2397 642 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 624/624
(100 %)
1 diff
(99.9 %id)
BG032257 breast, mammary adenocarcinoma, cell line .b 1782 to 2397 1 to 616   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 616/616
(100 %)
2 diff
(99.7 %id)
BQ424682 melanotic melanoma, skin .b 1788 to 2398 1 to 612       612/618
(99 %)
4 diff
(99.4 %id)
AI344338 colon, colon tumor, RER+ .b 1823 to 2400 581 to 3       579/581
(99 %)
0 diff
(100 %id)
AW051738 Kidney .b 1823 to 2398 575 to 1       575/575
(100 %)
5 diff
(99.2 %id)
BG392309 embryonal carcinoma, cell line, testis .b 1824 to 2397 1 to 574   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 574/574
(100 %)
9 diff
(98.5 %id)
BF881589 lung_tumor .b 1836 to 1968 14 to 145       132/145
(91 %)
6 diff
(95.9 %id)
N79689 multiple sclerosis lesions .b 1845 to 2292 1 to 454       454/454
(100 %)
13 diff
(97.2 %id)
W25574 heart .b 1861 to 2104 1 to 256   fully sequenced,   256/256
(100 %)
4 diff
(98.5 %id)
TI_149294462   .b 1863 to 2397 598 to 63   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 536/823
(65 %)
2 diff
(99.8 %id)
BU683220 lung .b 1867 to 2397 550 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 532/534
(99 %)
1 diff
(99.9 %id)
TI_151733058   .b 1869 to 2397 610 to 82   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 529/946
(55 %)
6 diff
(99.4 %id)
BQ188716 eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid .b 1878 to 2397 1 to 520   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 520/520
(100 %)
1 diff
(99.9 %id)
AI830337 colon, colon tumor, RER+ .b 1896 to 2398 504 to 1       504/504
(100 %)
1 diff
(99.9 %id)
AI859512 serous papillary carcinoma, high grade, 2pooled tumors, uterus .b 1899 to 2397 500 to 1       500/500
(100 %)
2 diff
(99.6 %id)
BF114931 Kidney .b 1899 to 2400 506 to 6       501/506
(99 %)
0 diff
(100 %id)
AW246762 lung, small cell carcinoma .b 1912 to 2397 496 to 11   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 486/486
(100 %)
0 diff
(100 %id)
AA405413 ovarian tumor, ovary .b 1917 to 2246 1 to 329       329/329
(100 %)
1 diff
(99.7 %id)
EC458745 Prostate .b 1923 to 2024 1 to 101       101/101
(100 %)
6 diff
(94.1 %id)
AW131795 brain, medulloblastoma .b 1923 to 2398 477 to 2       476/477
(99 %)
0 diff
(100 %id)
BE613170 adenocarcinoma, ovary .b 1927 to 2347 428 to 1   fully sequenced,   428/428
(100 %)
8 diff
(98.2 %id)
AI480203 anaplastic oligodendroglioma, brain .b 1932 to 2398 470 to 5       466/470
(99 %)
0 diff
(100 %id)
AI660449 colon, colonic mucosa from 3 patients with Crohn'sdisease .b 1932 to 2398 473 to 7       467/473
(98 %)
0 diff
(100 %id)
AI978690 uterus, well-differentiated endometrialadenocarcinoma, 7 pooled tumors .b 1933 to 2388 457 to 1       457/457
(100 %)
4 diff
(99.2 %id)
AI655134 pooled germ cell tumors .b 1939 to 2396 466 to 9       458/466
(98 %)
0 diff
(100 %id)
AW615216 Kidney .b 1940 to 2398 461 to 3       459/461
(99 %)
0 diff
(100 %id)
DB525151 testis .b 1958 to 2397 1 to 440     Submitted on the opposite strand 440/440
(100 %)
1 diff
(99.8 %id)
BF435851 pooled .b 1962 to 2398 442 to 6   tiling clone,   437/442
(98 %)
0 diff
(100 %id)
EC526164 Prostate .b 1970 to 2074 105 to 1       105/105
(100 %)
0 diff
(100 %id)
CD369603 Alveolar Macrophage, lung .b 1989 to 2397 427 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 409/409
(100 %)
1 diff
(99.8 %id)
DB525865 testis .b 1994 to 2397 1 to 404     Submitted on the opposite strand 404/405
(99 %)
3 diff
(99.3 %id)
AI926040 poorly differentiated adenocarcinoma withsignet ring cell features, stomach .b 2012 to 2398 387 to 1       387/387
(100 %)
2 diff
(99.5 %id)
AI718905 colon .b 2016 to 2398 385 to 3       383/385
(99 %)
0 diff
(100 %id)
AI139703 heart .b 2019 to 2397 395 to 17   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 379/379
(100 %)
1 diff
(99.8 %id)
AI336989 pooled germ cell tumors .b 2019 to 2396 386 to 9       378/386
(97 %)
0 diff
(100 %id)
AI469842 pooled .b 2020 to 2397 388 to 11   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 378/378
(100 %)
0 diff
(100 %id)
AI392737 B-cell, chronic lymphotic leukemia .b 2021 to 2397 390 to 14   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 377/377
(100 %)
1 diff
(99.8 %id)
BG163959 hypernephroma, cell line, Kidney .b 2046 to 2397 1 to 353   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 353/353
(100 %)
2 diff
(99.5 %id)
CB047438 Kidney .b 2050 to 2397 371 to 25   fully sequenced, AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 347/347
(100 %)
3 diff
(99.2 %id)
BP391086 pancreatic islet .b 2051 to 2398 1 to 348     Submitted on the opposite strand 348/351
(99 %)
4 diff
(98.9 %id)
BQ223219 large cell carcinoma, lung .b 2051 to 2397 1 to 347   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 347/347
(100 %)
3 diff
(99.2 %id)
AI268186 mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus .b 2056 to 2397 342 to 1       342/342
(100 %)
2 diff
(99.5 %id)
AI582333 lung, squamous cell carcinoma, poorlydifferentiated (4 pooled tumors, including primary andmetastatic) .b 2056 to 2397 390 to 49   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 342/342
(100 %)
19 diff
(94.5 %id)
W02503 heart .b 2074 to 2397 327 to 1   fully sequenced,   327/327
(100 %)
7 diff
(97.9 %id)
AI358269 poorly-differentiated endometrialadenocarcinoma, 2 pooled tumors, uterus .b 2082 to 2397 333 to 18   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 316/316
(100 %)
1 diff
(99.7 %id)
AW514612 moderately-differentiated endometrialadenocarcinoma, 3 pooled tumors, uterus .b 2086 to 2397 330 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 312/312
(100 %)
4 diff
(98.8 %id)
AA854749 parathyroid gland, parathyroid tumor .b 2094 to 2397 313 to 11   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 303/303
(100 %)
5 diff
(98.4 %id)
AI916166 colon, colon tumor, RER+ .b 2103 to 2397 321 to 27   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 295/295
(100 %)
7 diff
(97.7 %id)
AI669894 Prostate .b 2107 to 2397 301 to 12   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 290/290
(100 %)
2 diff
(99.4 %id)
BE256951 eye, retinoblastoma .b 2112 to 2768 1 to 651   tiling clone,   651/709
(91 %)
15 diff
(97.9 %id)
BE256988 eye, retinoblastoma .b 2112 to 2768 1 to 652   tiling clone,   652/769
(84 %)
16 diff
(98.0 %id)
AI383281 mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus .b 2121 to 2397 275 to 1       275/275
(100 %)
3 diff
(99.0 %id)
AI270131 esophagus, squamous cell carcinoma .b 2124 to 2398 282 to 8       275/282
(97 %)
0 diff
(100 %id)
AI206415 Kidney .b 2132 to 2397 295 to 30   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 266/266
(100 %)
3 diff
(98.9 %id)
BI762314 pooled colon, kidney, stomach .b 2158 to 2397 1 to 241   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 241/241
(100 %)
4 diff
(98.4 %id)
AI183699 lung .b 2161 to 2397 256 to 20   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 237/239
(99 %)
1 diff
(99.6 %id)
BM129442 Islets of Langerhans, Pancreas .b 2161 to 2397 247 to 11   fully sequenced, AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 237/237
(100 %)
1 diff
(99.6 %id)
BM126233 Islets of Langerhans, Pancreas .b 2170 to 2403 238 to 5   fully sequenced,   234/238
(98 %)
9 diff
(96.3 %id)
BM129477 Islets of Langerhans, Pancreas .b 2189 to 2401 219 to 7   fully sequenced,   213/219
(97 %)
6 diff
(97.3 %id)
AW169520 moderately-differentiated endometrialadenocarcinoma, 3 pooled tumors, uterus .b 2268 to 2397 144 to 15   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 130/130
(100 %)
1 diff
(99.3 %id)
AW513012 uterus, well-differentiated endometrialadenocarcinoma, 7 pooled tumors .b 2268 to 2397 142 to 13   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 130/130
(100 %)
0 diff
(100 %id)
AI373475 Kidney .b 2271 to 2398 136 to 9       128/136
(94 %)
0 diff
(100 %id)
BF476113 Kidney .b 2271 to 2398 136 to 9       128/136
(94 %)
0 diff
(100 %id)
EC534291 Prostate .b 2302 to 2395 106 to 13       94/106
(88 %)
0 diff
(100 %id)
BM561945 blood, natural killer cells, cell line .c 1 to 923 1 to 931   tiling clone,   931/1042
(89 %)
20 diff
(98.1 %id)
BQ051631 blood, natural killer cells, cell line .c 2 to 786 1 to 796       796/855
(93 %)
15 diff
(98.3 %id)
BQ054381 blood, natural killer cells, cell line .c 2 to 674 1 to 676       676/965
(70 %)
10 diff
(99.0 %id)
BE385460 melanotic melanoma, skin .c 524 to 1105 1 to 582   tiling clone,   582/583
(99 %)
2 diff
(99.7 %id)
BE409470 choriocarcinoma, placenta .c 525 to 1189 1 to 659   tiling clone,   659/671
(98 %)
7 diff
(99.0 %id)
AI081980 breast .d 1 to 461 1 to 461   tiling clone, Submitted on the opposite strand 461/461
(100 %)
2 diff
(99.6 %id)
BX384048   .d 62 to 654 1 to 592       592/953
(62 %)
16 diff
(98.4 %id)
BC015797 Uterus, leiomyosarcoma .d 72 to 2016 1 to 1945   tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 1945/1945
(100 %)
4 diff
(99.8 %id)
BQ222754 epithelioid carcinoma, Pancreas .d 80 to 654 1 to 575       575/923
(62 %)
4 diff
(99.6 %id)
DB026717 testis .d 85 to 648 2 to 566   capped   565/565
(100 %)
3 diff
(99.5 %id)
DB041735 testis .d 85 to 632 2 to 550   capped   549/549
(100 %)
2 diff
(99.7 %id)
BU597237 mixed (pool of 40 RNAs) .d 97 to 572 1 to 477       477/1085
(43 %)
13 diff
(98.9 %id)
DB460454 testis .d 100 to 572 1 to 473       473/480
(98 %)
4 diff
(99.2 %id)
DA284561 corpus callosum .d 120 to 429 2 to 311   capped   310/310
(100 %)
0 diff
(100 %id)
DA822840 pericardium .d 130 to 644 2 to 516   tiling clone, capped   515/515
(100 %)
0 diff
(100 %id)
DB186935 liver, tumor tissue .d 132 to 644 2 to 514   capped   513/513
(100 %)
0 diff
(100 %id)
CN304707 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .d 263 to 642 1 to 380       380/380
(100 %)
0 diff
(100 %id)
BX393212   .d 1092 to 2010 916 to 5   tiling clone,   912/919
(99 %)
0 diff
(100 %id)
CR992569 T-Lymphocytes .e 1 to 732 9 to 743   tiling clone,   743/745
(99 %)
7 diff
(99.1 %id)
AI834246 head_neck .e 688 to 903 1 to 216   tiling clone,   216/216
(100 %)
0 diff
(100 %id)
BU185212 ductal carcinoma, cell line, Pancreas .f 1 to 535 70 to 607   tiling clone,   538/1224
(43 %)
21 diff
(98.3 %id)
DA963522 stomach .f 13 to 537 2 to 526   capped   525/525
(100 %)
1 diff
(99.9 %id)
DA575634   .f 15 to 541 2 to 532   capped   531/531
(100 %)
8 diff
(98.5 %id)
BG703609 brain, hippocampus .f 18 to 853 1 to 839       837/842
(99 %)
16 diff
(98.1 %id)
BG470572 eye, retinoblastoma .f 23 to 782 1 to 761       761/768
(99 %)
8 diff
(99.0 %id)
BG473422 eye, retinoblastoma .f 23 to 771 1 to 754       754/754
(100 %)
9 diff
(98.9 %id)
AL528989 brain, neuroblastoma cells, Neuroblastoma Cot 50-normalized .f 24 to 781 1 to 756       756/756
(100 %)
20 diff
(97.4 %id)
AL530102 brain, neuroblastoma cells, Neuroblastoma Cot 50-normalized .f 31 to 891 15 to 872       858/872
(98 %)
13 diff
(98.6 %id)
BG328127 adenocarcinoma cell line, colon .f 32 to 860 1 to 818       818/937
(87 %)
33 diff
(96.5 %id)
BF972687 leiomyosarcoma cell line, uterus .f 33 to 788 1 to 768       768/907
(84 %)
30 diff
(96.7 %id)
BG468346 adenocarcinoma cell line, colon .f 33 to 917 1 to 896       896/990
(90 %)
29 diff
(97.1 %id)
DR155359 human embryonic stem cells differentiated toan early endodermal cell type .f 35 to 815 23 to 803       781/803
(97 %)
8 diff
(99.1 %id)
AL561008 B cells from Burkitt lymphoma .f 37 to 1042 24 to 1018 R9H W10G Y11T F12S L15W ... fully sequenced,   995/1018
(97 %)
13 diff
(98.8 %id)
BM921154 pooled brain, lung, testis .f 46 to 782 8 to 745   tiling clone,   738/1080
(68 %)
10 diff
(99.1 %id)
DT220438 brain .f 52 to 704 1 to 653       653/653
(100 %)
1 diff
(99.9 %id)
BE907122 epithelioid carcinoma, Pancreas .f 53 to 768 1 to 713       713/730
(97 %)
11 diff
(98.5 %id)
BE885422 leiomyosarcoma, uterus .f 55 to 770 1 to 716       716/864
(82 %)
20 diff
(97.7 %id)
BU181006 large cell carcinoma, lung .f 55 to 865 1 to 815       813/888
(91 %)
8 diff
(99.1 %id)
BI757323 brain .f 56 to 926 1 to 889       887/1134
(78 %)
33 diff
(97.1 %id)
TI_57220535   .f 56 to 926 33 to 921       887/1166
(76 %)
33 diff
(97.2 %id)
BJ990796 hepatoblastoma .f 57 to 642 1 to 586       586/586
(100 %)
1 diff
(99.9 %id)
BG488893 large cell carcinoma, lung .f 62 to 795 1 to 737       737/737
(100 %)
5 diff
(99.4 %id)
TI_57174314   .f 62 to 737 28 to 702       675/702
(96 %)
7 diff
(99.1 %id)
BX443413 T cells (Jurkat cell line) .f 64 to 736 33 to 704       672/704
(95 %)
22 diff
(96.9 %id)
BG333804 melanotic melanoma, skin .f 68 to 851 1 to 782       782/893
(87 %)
20 diff
(97.8 %id)
BI826903 brain, medulla .f 68 to 737 1 to 669       669/669
(100 %)
2 diff
(99.8 %id)
BC007355 Skin, melanotic melanoma. .f 69 to 1952 1 to 1884 exact tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 1884/1884
(100 %)
1 diff
(100.0 %id)
NM_012140.3   .f 69 to 1952 1 to 1884 exact RefSeq, AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 1884/1884
(100 %)
1 diff
(100.0 %id)
TI_57147240   .f 70 to 948 29 to 924       896/927
(96 %)
36 diff
(96.2 %id)
TI_57170400   .f 71 to 920 59 to 930       868/961
(90 %)
30 diff
(96.9 %id)
BI764774 pooled colon, kidney, stomach .f 74 to 926 1 to 870       870/895
(97 %)
31 diff
(96.6 %id)
BI825509 brain, medulla .f 76 to 920 1 to 867       863/898
(96 %)
33 diff
(96.4 %id)
AK075249 thyroid gland .f 80 to 1952 1 to 1872 exact tiling clone, available from FLJ,   1872/1872
(100 %)
5 diff
(99.8 %id)
BG481208 choriocarcinoma, placenta .f 80 to 789 1 to 708       708/708
(100 %)
2 diff
(99.8 %id)
BG428545 Kidney .f 81 to 865 1 to 788       785/824
(95 %)
28 diff
(96.7 %id)
DB166143 thyroid gland .f 81 to 852 2 to 775   capped   774/781
(99 %)
13 diff
(98.4 %id)
DA429862 colon .f 83 to 645 2 to 564   capped   563/563
(100 %)
0 diff
(100 %id)
DA429889 colon .f 83 to 638 2 to 558   capped   557/557
(100 %)
2 diff
(99.7 %id)
DA630418 Kidney .f 83 to 655 2 to 574   capped   573/573
(100 %)
0 diff
(100 %id)
BM924696 pooled colon, kidney, stomach .f 88 to 1016 1 to 930       930/1097
(84 %)
14 diff
(98.8 %id)
BI829776 brain, medulla .f 89 to 949 1 to 858       858/859
(99 %)
8 diff
(99.1 %id)
DA615728   .f 89 to 656 2 to 570   capped   569/569
(100 %)
2 diff
(99.7 %id)
TI_57176341   .f 89 to 949 29 to 886       858/887
(96 %)
14 diff
(98.5 %id)
AL561029 B cells from Burkitt lymphoma .f 90 to 1026 1 to 927 R9P W10G Y11T F12S L15W ... fully sequenced,   927/927
(100 %)
22 diff
(97.7 %id)
BU176451 eye, retinoblastoma .f 92 to 852 7 to 776       768/928
(82 %)
29 diff
(96.9 %id)
BE895901 melanotic melanoma, skin .f 93 to 825 1 to 731       731/1046
(69 %)
26 diff
(97.6 %id)
BQ278977 adenocarcinoma, cell line, breast .f 93 to 952 1 to 858       858/967
(88 %)
5 diff
(99.5 %id)
DB189800 lung, tumor tissue .f 93 to 659 2 to 569   capped   568/568
(100 %)
2 diff
(99.7 %id)
DA006824   .f 94 to 676 2 to 584   capped   583/583
(100 %)
1 diff
(99.9 %id)
BF683556 leiomyosarcoma cell line, uterus .f 94 to 860 1 to 762       762/866
(87 %)
15 diff
(98.3 %id)
BF984112 duodenal adenocarcinoma, cell line, small intestine .f 95 to 788 1 to 691       691/706
(97 %)
10 diff
(98.6 %id)
DA621368 Kidney .f 95 to 656 2 to 563   capped   562/562
(100 %)
1 diff
(99.9 %id)
DA635863 Kidney .f 95 to 661 2 to 568   capped   567/567
(100 %)
0 diff
(100 %id)
DA912339   .f 95 to 664 2 to 571   capped   570/570
(100 %)
1 diff
(99.9 %id)
DB185410 liver, tumor tissue .f 95 to 656 2 to 564   capped   563/563
(100 %)
1 diff
(99.9 %id)
BI830670 brain, medulla .f 97 to 807 1 to 712       712/712
(100 %)
10 diff
(98.6 %id)
TI_57172841   .f 97 to 807 65 to 776       712/776
(91 %)
13 diff
(98.4 %id)
CN304708 embryonic stem cells, DMSO-treated H9 cellline .f 103 to 766 1 to 664       664/664
(100 %)
3 diff
(99.6 %id)
DB182207 liver, tumor tissue .f 105 to 678 2 to 575   capped   574/574
(100 %)
0 diff
(100 %id)
CX752920 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .f 109 to 841 1 to 733     Submitted on the opposite strand 733/733
(100 %)
2 diff
(99.8 %id)
AJ131613 Liver .f 126 to 1957 1 to 1837 L188R AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 1837/1837
(100 %)
11 diff
(99.5 %id)
BQ647558 hepatocellular carcinoma, cell line, Liver .f 127 to 967 6 to 847       842/891
(94 %)
17 diff
(98.1 %id)
BI226141 Burkitt lymphoma, lymph .f 131 to 861 1 to 731       731/731
(100 %)
1 diff
(99.9 %id)
BM458125 leiomyosarcoma, uterus .f 131 to 1030 1 to 904 E233S Y234I Q235R G236A V237F ...     904/1025
(88 %)
16 diff
(98.5 %id)
BM552299 leiomyosarcoma, uterus .f 131 to 1029 1 to 903 G236X F252L Y253L K254Q V268G ...     903/978
(92 %)
15 diff
(98.5 %id)
BE783913 eye, retinoblastoma .f 140 to 781 1 to 643       643/648
(99 %)
4 diff
(99.4 %id)
BG831836 epithelioid carcinoma cell line, Pancreas .f 146 to 1005 1 to 854       854/854
(100 %)
14 diff
(98.4 %id)
TI_1948074385   .f 149 to 604 138 to 592   fully sequenced,   455/592
(76 %)
6 diff
(99.0 %id)
DR432951 mixed .f 150 to 604 1 to 455   fully sequenced,   455/455
(100 %)
3 diff
(99.4 %id)
DR432658 mixed .f 150 to 604 1 to 455   fully sequenced,   455/455
(100 %)
3 diff
(99.4 %id)
DR433087 mixed .f 150 to 604 1 to 455   fully sequenced,   455/455
(100 %)
3 diff
(99.4 %id)
DR432642 mixed .f 150 to 604 1 to 455   fully sequenced,   455/455
(100 %)
3 diff
(99.4 %id)
DR433035 mixed .f 150 to 722 1 to 573   fully sequenced,   573/573
(100 %)
5 diff
(99.2 %id)
DR432650 mixed .f 150 to 604 1 to 455   fully sequenced,   455/455
(100 %)
4 diff
(99.2 %id)
BQ880288 brain, neuroblastoma, cell line .f 151 to 917 36 to 804       769/972
(79 %)
14 diff
(98.6 %id)
TI_1948074759   .f 154 to 1017 127 to 993       867/1282
(67 %)
20 diff
(98.5 %id)
TI_1948074943   .f 154 to 260 129 to 235   fully sequenced,   107/133
(80 %)
6 diff
(95.5 %id)
CV023316 mixed .f 155 to 1050 1 to 631       631/631
(100 %)
1 diff
(99.9 %id)
CV027219 mixed .f 155 to 732 1 to 578       578/578
(100 %)
1 diff
(99.9 %id)
BE547111 cervical carcinoma cell line, cervix .f 162 to 917 1 to 788       682/794
(85 %)
34 diff
(95.8 %id)
BQ943394 large cell carcinoma, lung .f 176 to 917 1 to 745       745/950
(78 %)
8 diff
(99.2 %id)
BM564404 duodenal adenocarcinoma, cell line, small intestine .f 177 to 782 1 to 606       606/1132
(53 %)
3 diff
(99.8 %id)
BE873134 adenocarcinoma, colon .f 183 to 917 1 to 737       737/884
(83 %)
14 diff
(98.5 %id)
AW327369 blood, T cell leukemia .f 193 to 672 1 to 480       480/480
(100 %)
1 diff
(99.8 %id)
TI_1948074944   .f 239 to 1021 906 to 122   fully sequenced,   785/906
(86 %)
13 diff
(98.6 %id)
TI_1948074572   .f 246 to 1021 898 to 122       777/1316
(59 %)
16 diff
(98.8 %id)
AW249011 lung, small cell carcinoma .f 307 to 952 9 to 654     Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 646/654
(98 %)
2 diff
(99.7 %id)
BQ065993 lymph, lymphoma, cell line .f 314 to 1091 1 to 789       789/1069
(73 %)
17 diff
(98.5 %id)
DR432956 mixed .f 543 to 1021 480 to 2   fully sequenced,   479/480
(99 %)
0 diff
(100 %id)
DR432664 mixed .f 543 to 1021 480 to 2   fully sequenced,   479/480
(99 %)
0 diff
(100 %id)
DR433084 mixed .f 543 to 1021 479 to 2   fully sequenced,   478/479
(99 %)
3 diff
(99.4 %id)
DR432636 mixed .f 543 to 1021 480 to 2   fully sequenced,   479/480
(99 %)
0 diff
(100 %id)
DR432646 mixed .f 543 to 1021 480 to 2   fully sequenced,   479/480
(99 %)
0 diff
(100 %id)
TI_1948074386   .f 543 to 1021 602 to 122   fully sequenced,   481/602
(79 %)
2 diff
(99.7 %id)
BX441755 brain, fetal brain .f 571 to 1416 1 to 844       844/844
(100 %)
6 diff
(99.3 %id)
BX463989 brain, fetal brain .f 571 to 1560 1 to 980       980/1026
(95 %)
22 diff
(97.9 %id)
BX444989 brain, fetal brain .f 571 to 1243 1 to 675   fully sequenced,   675/675
(100 %)
26 diff
(96.2 %id)
AA290840 ovarian tumor, ovary .f 592 to 839 1 to 250       248/251
(98 %)
20 diff
(92.1 %id)
BQ920816 epidermoid carcinoma, cell line, lung .f 613 to 1508 1 to 905       905/908
(99 %)
17 diff
(98.2 %id)
DR433041 mixed .f 692 to 1021 331 to 2   fully sequenced,   330/331
(99 %)
0 diff
(100 %id)
CD557336 testis .f 702 to 1223 15 to 541       527/1001
(52 %)
20 diff
(98.1 %id)
BG981453 colon_normal .f 706 to 1038 337 to 3       335/337
(99 %)
0 diff
(100 %id)
BQ650269 hepatocellular carcinoma, cell line, Liver .f 720 to 1431 1 to 717       717/931
(77 %)
17 diff
(98.2 %id)
BQ652078 hepatocellular carcinoma, cell line, Liver .f 720 to 1533 1 to 819       819/940
(87 %)
32 diff
(96.6 %id)
BQ644236 hepatocellular carcinoma, cell line, Liver .f 720 to 1552 1 to 831       831/930
(89 %)
33 diff
(96.5 %id)
DR759761 embryonic stem .f 740 to 1549 1 to 810       810/810
(100 %)
6 diff
(99.3 %id)
BQ645907 hepatocellular carcinoma, cell line, Liver .f 795 to 1638 1 to 851       851/870
(97 %)
20 diff
(97.8 %id)
BF745441 breast .f 809 to 1107 1 to 302       302/302
(100 %)
17 diff
(94.4 %id)
AW879661 ovary .f 857 to 1083 70 to 300       229/300
(76 %)
11 diff
(96.4 %id)
BG286805 bladder, transitional cell papilloma, cell line .f 906 to 1705 1 to 788       788/789
(99 %)
19 diff
(97.6 %id)
AL582334 B cells from Burkitt lymphoma .f 996 to 1907 916 to 11   fully sequenced,   906/916
(98 %)
21 diff
(97.8 %id)
AL582314 B cells from Burkitt lymphoma .f 1012 to 1912 904 to 10   fully sequenced,   895/904
(99 %)
7 diff
(99.3 %id)
AL530101 brain, neuroblastoma cells, Neuroblastoma Cot 50-normalized .f 1044 to 1912 863 to 1       863/863
(100 %)
25 diff
(97.2 %id)
BX444988 brain, fetal brain .f 1213 to 1915 709 to 1   fully sequenced,   709/709
(100 %)
33 diff
(95.4 %id)
AW248571 lung, small cell carcinoma .f 1396 to 1952 566 to 11   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 556/556
(100 %)
2 diff
(99.7 %id)
BJ990797 hepatoblastoma .f 1425 to 1901 476 to 1       476/480
(99 %)
3 diff
(99.4 %id)
DB382092 thyroid gland .f 1429 to 1952 523 to 1       523/527
(99 %)
22 diff
(95.9 %id)
AA285019 ovarian tumor, ovary .f 1542 to 1953 414 to 2       413/414
(99 %)
0 diff
(100 %id)
CX762377 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .g 1 to 780 1 to 773   tiling clone, Submitted on the opposite strand 773/776
(99 %)
40 diff
(94.9 %id)
CR991771 T-Lymphocytes .g 644 to 1275 1 to 632   tiling clone,   632/632
(100 %)
0 diff
(100 %id)
TI_57181694   .h-u 1 to 791 32 to 819   tiling clone,   788/821
(95 %)
9 diff
(99.0 %id)
BI767295 pooled lung and spleen .h-u 5 to 791 1 to 784   tiling clone,   784/786
(99 %)
7 diff
(99.2 %id)
BQ925755 sciatic nerve .h-u 48 to 518 1 to 473       473/1178
(40 %)
9 diff
(99.3 %id)
AW629684 2 pooled high-grade transitional celltumors, genitourinary tract .h-u 335 to 791 1 to 457   tiling clone,   457/457
(100 %)
0 diff
(100 %id)
AK097197 Spleen .h-u 344 to 3454 1 to 3103 exact tiling clone, available from FLJ,   3103/3103
(100 %)
22 diff
(99.3 %id)
DA941738 Spleen .h-u 345 to 886 2 to 538   capped   537/537
(100 %)
2 diff
(99.7 %id)
CR976361 T-Lymphocytes .h-u 381 to 643 1 to 263       263/265
(99 %)
2 diff
(99.3 %id)
BM685218 eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid .h-u 1408 to 1746 13 to 351   fully sequenced, AAA Submitted on the opposite strand 339/351
(96 %)
5 diff
(98.6 %id)
AW451063   .h-u 1415 to 1877 18 to 478   AAA Submitted on the opposite strand 461/478
(96 %)
6 diff
(98.8 %id)
BU689032 lung .h-u 1415 to 2102 19 to 706   AAA Submitted on the opposite strand 688/707
(97 %)
3 diff
(99.6 %id)
BM991037 lung, Lung Focal Fibrosis .h-u 1416 to 2041 19 to 643   tiling clone, AAA Submitted on the opposite strand 625/643
(97 %)
6 diff
(99.1 %id)
BF508230   .h-u 1417 to 1763 12 to 357   AAA Submitted on the opposite strand 346/357
(96 %)
6 diff
(98.4 %id)
BM932225 eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid .h-u 1716 to 2214 497 to 1   tiling clone, fully sequenced, Submitted on the opposite strand 497/497
(100 %)
5 diff
(99.0 %id)
BE874859 large cell carcinoma, undifferentiated, lung .h-u 1725 to 2528 808 to 1     Submitted on the opposite strand 808/969
(83 %)
35 diff
(96.4 %id)
BG924716 cartilage .h-u 1769 to 2231 549 to 86       464/481
(96 %)
0 diff
(100 %id)
AL534133 brain, fetal brain .i 1 to 1027 1 to 1019   tiling clone,   1019/1019
(100 %)
14 diff
(98.7 %id)
CR998287 T-Lymphocytes .i 41 to 582 1 to 542       542/543
(99 %)
2 diff
(99.7 %id)
BI560709 testis .i 65 to 877 1 to 817       817/818
(99 %)
24 diff
(97.1 %id)
TI_44349699   .i 70 to 877 91 to 902       812/903
(89 %)
28 diff
(96.9 %id)
DB459711 testis .i 72 to 522 1 to 451       451/451
(100 %)
0 diff
(100 %id)
BF980830 duodenal adenocarcinoma, cell line, small intestine .i 74 to 831 1 to 760   tiling clone,   760/971
(78 %)
10 diff
(99.0 %id)
DN996600 breast cancer, Mammary gland (cancer tissue) .i 136 to 654 1 to 519       519/519
(100 %)
5 diff
(99.1 %id)
DA825430 pericardium .i 306 to 831 2 to 527   capped   526/526
(100 %)
0 diff
(100 %id)
DA047624   .i 429 to 1003 2 to 576   capped   575/575
(100 %)
0 diff
(100 %id)
AK303808 liver, tumor tissue .i 437 to 1523 1 to 1087 exact tiling clone,   1087/1087
(100 %)
2 diff
(99.9 %id)
DB188349 liver, tumor tissue .i 438 to 1013 2 to 577   capped   576/576
(100 %)
1 diff
(99.9 %id)
CB111910 Liver .i 466 to 1013 1 to 548       548/548
(100 %)
0 diff
(100 %id)
CF146331 CNCAP(3)T-225 cell line, Prostate .i 471 to 789 9 to 327       319/333
(95 %)
14 diff
(95.8 %id)
DA382752 thalamus .i 473 to 1042 2 to 571   tiling clone, capped   570/570
(100 %)
0 diff
(100 %id)
DA539753 Kidney .i 477 to 1035 2 to 561   capped   560/569
(98 %)
1 diff
(99.9 %id)
AL565392 brain, fetal brain .i 1219 to 2179 953 to 4   tiling clone,   950/968
(98 %)
0 diff
(100 %id)
BM470204 lymph, lymphoma, cell line .j 1 to 907 1 to 921 exact tiling clone,   919/1020
(90 %)
21 diff
(98.0 %id)
AK294190 amygdala .k 1 to 1004 1 to 1004 E90G tiling clone,   1004/1004
(100 %)
1 diff
(100.0 %id)
AA164739 Pancreas .k 121 to 695 1 to 575   tiling clone,   575/577
(99 %)
7 diff
(98.8 %id)
BF811204 colon_ins .k 1270 to 1612 27 to 371   tiling clone,   345/375
(92 %)
6 diff
(98.4 %id)
AA161299 Pancreas .k 1520 to 2188 655 to 1   tiling clone,   655/665
(98 %)
15 diff
(97.8 %id)
AI825905 poorly differentiated adenocarcinoma withsignet ring cell features, stomach .k 1682 to 2188 507 to 1   tiling clone,   507/507
(100 %)
2 diff
(99.7 %id)
BX115814 poorly differentiated adenocarcinoma withsignet ring cell features, stomach .k 1727 to 2198 476 to 5   tiling clone, Submitted on the opposite strand 472/476
(99 %)
0 diff
(100 %id)
AW843904 colon_normal .k 1753 to 1910 16 to 173       158/173
(91 %)
6 diff
(96.6 %id)
CR744522 poorly differentiated adenocarcinoma withsignet ring cell features, stomach .k 1753 to 2198 450 to 5     Submitted on the opposite strand 446/450
(99 %)
0 diff
(100 %id)
AI354376 esophagus, squamous cell carcinoma .k 1766 to 2188 422 to 1       422/422
(100 %)
1 diff
(99.8 %id)
AW081897 esophagus, squamous cell carcinoma .k 1776 to 2188 413 to 1       413/413
(100 %)
0 diff
(100 %id)
CD172482 White Matter .l 1 to 809 28 to 845 E190G Y191V Q192S G193X V194A ... tiling clone,   818/893
(91 %)
17 diff
(98.1 %id)
BQ648624 hepatocellular carcinoma, cell line, Liver .m 1 to 620 1 to 620 R21* tiling clone,   620/922
(67 %)
12 diff
(98.7 %id)
AA236138 germinal center B cell .n 1 to 330 1 to 329   tiling clone,   329/329
(100 %)
7 diff
(97.9 %id)
AK026523   .n 306 to 2282 1977 to 1   tiling clone, available from FLJ, Submitted on the opposite strand 1977/2002
(98 %)
0 diff
(100 %id)
BX434887 brain, fetal brain .n 310 to 1210 1 to 907     Submitted on the opposite strand 907/907
(100 %)
13 diff
(98.6 %id)
BX412997 brain, fetal brain .n 313 to 1169 1 to 859       859/913
(94 %)
32 diff
(96.5 %id)
BX451445 brain, fetal brain .n 535 to 1440 924 to 20     Submitted on the opposite strand 905/924
(97 %)
0 diff
(100 %id)
BX451444 brain, fetal brain .n 585 to 1445 868 to 6     Submitted on the opposite strand 863/870
(99 %)
0 diff
(100 %id)
CK903781 Islets of Langerhans, Pancreas .n 886 to 1102 1 to 217   AAA   217/219
(99 %)
1 diff
(99.6 %id)
AA236046 germinal center B cell .n 895 to 975 80 to 1       80/80
(100 %)
1 diff
(98.8 %id)
BE675204 B-cell, chronic lymphotic leukemia .n 1092 to 1524 1 to 433     Submitted on the opposite strand 433/433
(100 %)
0 diff
(100 %id)
BQ924296 sciatic nerve .n 1092 to 1904 826 to 11     Submitted on the opposite strand 816/1063
(76 %)
0 diff
(100 %id)
AI363157 brain, glioblastoma (pooled) .n 1105 to 1554 1 to 450     Submitted on the opposite strand 450/450
(100 %)
0 diff
(100 %id)
BG054705 brain, glioblastoma (pooled) .n 1120 to 1600 1 to 481     Submitted on the opposite strand 481/481
(100 %)
0 diff
(100 %id)
BM919112 pooled pancreas and spleen .n 1345 to 2272 956 to 20     Submitted on the opposite strand 937/1067
(87 %)
0 diff
(100 %id)
BX460370 brain, fetal brain .n 1348 to 2236 889 to 1     Submitted on the opposite strand 889/889
(100 %)
2 diff
(99.8 %id)
BF340935 brain, glioblastoma with EGFR amplification .n 1574 to 2264 684 to 1     Submitted on the opposite strand 684/684
(100 %)
11 diff
(98.4 %id)
BM424183 amelanotic melanoma, cell line, skin .n 1631 to 2554 1 to 928       928/980
(94 %)
21 diff
(97.9 %id)
BM809112 amelanotic melanoma, cell line, skin .n 1632 to 2566 1 to 940   tiling clone,   940/1022
(91 %)
25 diff
(97.6 %id)
BE263443 lung, small cell carcinoma .n 1685 to 2235 551 to 1     Submitted on the opposite strand 551/551
(100 %)
3 diff
(99.5 %id)
BM787759 stomach .n 1740 to 2277 538 to 1     Submitted on the opposite strand 538/538
(100 %)
0 diff
(100 %id)
AW134988   .n 1890 to 2499 610 to 1       610/610
(100 %)
4 diff
(99.4 %id)
AI937435 anaplastic oligodendroglioma, brain .n 1952 to 2500 549 to 1       549/549
(100 %)
3 diff
(99.5 %id)
BQ277600 ovary, teratocarcinoma, cell line .n 2339 to 3065 1 to 730       730/1148
(63 %)
9 diff
(99.3 %id)
X79865 adenocarcinoma .n 2346 to 3356 1 to 1008 A33T     1008/1008
(100 %)
11 diff
(99.0 %id)
DA470104   .n 2350 to 2929 2 to 581   capped   580/581
(99 %)
3 diff
(99.5 %id)
BM761901 myeloma .n 2351 to 2942 1 to 592       592/592
(100 %)
2 diff
(99.7 %id)
BM849543 myeloma .n 2351 to 2960 1 to 611       611/611
(100 %)
5 diff
(99.2 %id)
DA648796   .n 2353 to 2913 2 to 562   capped   561/561
(100 %)
0 diff
(100 %id)
NM_002949.2   .n 2359 to 3358 1 to 1000 exact RefSeq, AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 1000/1000
(100 %)
0 diff
(100 %id)
BM845325 myeloma .n 2360 to 2468 1 to 109       109/109
(100 %)
0 diff
(100 %id)
BF316138 brain, neuroblastoma .n 2361 to 3088 1 to 717 E136R A137R K138S P139R V140G ...     717/1046
(68 %)
21 diff
(98.0 %id)
BG488665 large cell carcinoma, lung .n 2361 to 2990 1 to 630       630/630
(100 %)
1 diff
(99.9 %id)
BG775114 carcinoma, cell line, Prostate .n 2361 to 2859 1 to 501   fully sequenced,   501/501
(100 %)
3 diff
(99.5 %id)
BM048368 carcinoma, cell line, Prostate .n 2361 to 3033 1 to 675       675/675
(100 %)
5 diff
(99.3 %id)
BG104344 melanotic melanoma, skin .n 2362 to 3226 1 to 861 L188W E189K A190R V191W G192A ...     861/961
(89 %)
37 diff
(96.2 %id)
BM917243 blood, natural killer cells, cell line .n 2362 to 3246 1 to 886 K63Q I64D Q65T Q66A L67A ...     886/1015
(87 %)
9 diff
(99.2 %id)
BQ278969 adenocarcinoma, cell line, breast .n 2362 to 3181 1 to 838 K178Q A187G L188P E189W A190E ...     838/1010
(82 %)
27 diff
(97.4 %id)
BM794188 Ascites, stomach .n 2362 to 2895 1 to 534       534/534
(100 %)
0 diff
(100 %id)
BI083963 epidermoid carcinoma, cell line, salivary gland .n 2363 to 2859 1 to 497   fully sequenced,   497/497
(100 %)
0 diff
(100 %id)
BQ961668 epithelioid carcinoma cell line, Pancreas .n 2364 to 3171 1 to 819 S105P I172S N175M V176S A177P ...     819/921
(88 %)
24 diff
(97.4 %id)
BU527054 epidermoid carcinoma, cell line, lung .n 2364 to 3250 1 to 895 E189X     895/897
(99 %)
16 diff
(98.3 %id)
BU169210 epidermoid carcinoma, cell line, salivary gland .n 2365 to 3141 1 to 790 L158P V159R Q160P A161G K163E ...     790/937
(84 %)
24 diff
(97.5 %id)
BQ671509 epidermoid carcinoma, cell line, salivary gland .n 2365 to 3141 1 to 788 L164P V165G E166G S167V L168P ...     788/966
(81 %)
24 diff
(97.6 %id)
BM011077 brain, neuroblastoma, cell line .n 2366 to 3175 1 to 818 V140R D141G K142Q V143S K144E ...     818/819
(99 %)
15 diff
(98.2 %id)
BQ927283 large cell carcinoma, lung .n 2366 to 3248 1 to 886 exact     886/899
(98 %)
7 diff
(99.3 %id)
BM763843 myeloma .n 2366 to 2824 9 to 467       459/459
(100 %)
0 diff
(100 %id)
BM700069 eye, lens .n 2366 to 2775 1 to 410   fully sequenced, Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 410/410
(100 %)
0 diff
(100 %id)
BC002344 Muscle, rhabdomyosarcoma .n 2367 to 3358 1 to 992 exact tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 992/992
(100 %)
1 diff
(99.9 %id)
CN270378 embryonic stem cells, cell lines H1, H7, andH9 .n 2367 to 3018 1 to 652       652/652
(100 %)
2 diff
(99.7 %id)
TI_59379970   .n 2367 to 3175 102 to 918 V140R D141G K142Q V143S K144E ...     817/818
(99 %)
14 diff
(98.3 %id)
CF128137 Chondrosarcoma Lung Metastasis cell lines, lung .n 2369 to 3068 1 to 700       700/700
(100 %)
2 diff
(99.8 %id)
TI_154193970   .n 2369 to 3328 51 to 1011 K178X A186G A187G     961/964
(99 %)
20 diff
(98.0 %id)
BG475894 melanotic melanoma, skin .n 2371 to 3267 1 to 883 A174P N175I K185P L188W E189R ...     883/883
(100 %)
36 diff
(96.0 %id)
BQ051633 blood, natural killer cells, cell line .n 2371 to 3245 1 to 878 exact     878/918
(95 %)
10 diff
(99.0 %id)
BI084098 epidermoid carcinoma, cell line, salivary gland .n 2372 to 2859 1 to 488   fully sequenced,   488/488
(100 %)
0 diff
(100 %id)
BM914645 amelanotic melanoma, cell line, skin .n 2373 to 3099 19 to 745 E180D K185Q A186R A187P L188W ...     727/1125
(64 %)
15 diff
(98.7 %id)
BM043380 carcinoma, cell line, Prostate .n 2374 to 3161 1 to 789 A187G     789/791
(99 %)
4 diff
(99.5 %id)
BQ957698 carcinoma, cell line, Prostate .n 2376 to 3247 1 to 883 V191G     883/916
(96 %)
23 diff
(97.5 %id)
BG491480 amelanotic melanoma, cell line, skin .n 2377 to 2859 1 to 483   fully sequenced,   483/483
(100 %)
1 diff
(99.8 %id)
BM556222 amelanotic melanoma, cell line, skin .n 2378 to 3305 1 to 943 exact     943/1059
(89 %)
22 diff
(98.0 %id)
BM915820 amelanotic melanoma, cell line, skin .n 2378 to 3223 25 to 875 exact     851/1031
(82 %)
37 diff
(96.5 %id)
BE280159 choriocarcinoma, placenta .n 2381 to 3109 1 to 728 A19C A20C F21V R22P L23P ...     726/735
(98 %)
17 diff
(97.7 %id)
BE278830 choriocarcinoma, placenta .n 2381 to 3064 1 to 683       683/764
(89 %)
6 diff
(99.3 %id)
BE901808 choriocarcinoma, placenta .n 2382 to 3009 1 to 632       632/632
(100 %)
2 diff
(99.7 %id)
BQ896957 ductal carcinoma, cell line, Pancreas .n 2382 to 3195 1 to 825 E189G A190G V191G T194H V195P ...     825/864
(95 %)
22 diff
(97.5 %id)
BE900280 choriocarcinoma, placenta .n 2383 to 3112 1 to 726 L2C P3R A4R A5R A6S ...     726/730
(99 %)
7 diff
(99.1 %id)
BE900409 choriocarcinoma, placenta .n 2383 to 2977 1 to 593       593/593
(100 %)
2 diff
(99.7 %id)
BU179533 melanotic melanoma, cell line, skin .n 2384 to 3218 1 to 846 S105P     846/930
(90 %)
30 diff
(96.8 %id)
BF219688 muscle, rhabdomyosarcoma .n 2386 to 2933 1 to 548       548/548
(100 %)
0 diff
(100 %id)
BE279049 choriocarcinoma, placenta .n 2386 to 3027 1 to 638       638/697
(91 %)
7 diff
(99.0 %id)
BE388518 endometrium, adenocarcinoma cell line, uterus .n 2386 to 3062 1 to 673       673/736
(91 %)
8 diff
(99.0 %id)
BQ686580 ductal carcinoma, cell line, Pancreas .n 2387 to 3130 1 to 753 A187G G193R T194H V195R V196G ...     753/954
(78 %)
19 diff
(98.1 %id)
BE385873 melanotic melanoma, skin .n 2390 to 3062 1 to 670       670/806
(83 %)
11 diff
(98.7 %id)
CN270376 embryonic stem cells, cell lines H1, H7, andH9 .n 2405 to 2968 1 to 564       564/564
(100 %)
1 diff
(99.9 %id)
TI_154190199   .n 2424 to 3206 50 to 816 D54G N55*     767/879
(87 %)
18 diff
(98.0 %id)
CF127087 Chondrosarcoma Lung Metastasis cell lines, lung .n 2425 to 3026 1 to 603       603/603
(100 %)
1 diff
(99.9 %id)
BG823792 adenocarcinoma cell line, colon .n 2433 to 3047 1 to 615       615/615
(100 %)
6 diff
(99.1 %id)
CD388586 embryonic trophoblasts, made from WA01 stemcells .n 2434 to 3270 29 to 882 exact     854/886
(96 %)
43 diff
(95.2 %id)
BU556920 ovary, teratocarcinoma, cell line .n 2434 to 3199 1 to 777 exact     777/1047
(74 %)
21 diff
(98.0 %id)
BM719190 eye, fetal eye .n 2434 to 3035 1 to 602       602/602
(100 %)
0 diff
(100 %id)
BF313362 brain, neuroblastoma .n 2435 to 3160 1 to 723 L158S V159S Q160R A161Q K162R ...     723/900
(80 %)
6 diff
(99.4 %id)
BI196394 brain, neuroblastoma .n 2435 to 3357 1 to 916 N175Q V176C A177R K178Q A179K ...     916/922
(99 %)
27 diff
(97.1 %id)
TI_149313399   .n 2438 to 3358 998 to 88 L2R P3A A5R A6P R7X ... AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 911/1008
(90 %)
25 diff
(97.6 %id)
AW163544 brain, frontal lobe .n 2445 to 2829 1 to 385   fully sequenced,   385/385
(100 %)
1 diff
(99.8 %id)
BG396857 eye, retinoblastoma .n 2447 to 2986 1 to 540       540/540
(100 %)
1 diff
(99.9 %id)
BG761405 melanotic melanoma, high MDR (cell line), skin .n 2448 to 3203 1 to 752 P169X     752/752
(100 %)
7 diff
(99.1 %id)
BQ679050 melanotic melanoma, cell line, skin .n 2450 to 2738 1 to 289       289/289
(100 %)
0 diff
(100 %id)
BQ683225 melanotic melanoma, cell line, skin .n 2450 to 3185 1 to 737 K173Q K178Q     737/979
(75 %)
20 diff
(98.0 %id)
BQ678082 melanotic melanoma, cell line, skin .n 2450 to 3126 1 to 683 Q170P E171G I172N K173Q A174S ...     683/978
(69 %)
27 diff
(97.3 %id)
BQ681619 melanotic melanoma, cell line, skin .n 2450 to 3269 1 to 821 exact     821/910
(90 %)
20 diff
(97.9 %id)
BF663070 B-cells, primary B-cells from tonsils (cell line) .n 2451 to 3204 1 to 744 A174D L188W E189R A190R V191W ...     744/847
(87 %)
21 diff
(97.6 %id)
BU855778 ovary, teratocarcinoma, cell line .n 2451 to 3245 1 to 801 exact AAA   801/934
(85 %)
9 diff
(99.1 %id)
BF207350 brain, neuroblastoma .n 2452 to 3197 1 to 733 L2C P3R A4R A5R A6S ...     733/909
(80 %)
18 diff
(98.1 %id)
BU528367 epidermoid carcinoma, cell line, lung .n 2452 to 3343 32 to 928 exact     897/928
(96 %)
25 diff
(97.4 %id)
CD048155 embryonic stem cells, WA01, passage 38 .n 2453 to 3269 23 to 840 M104V R127W K185R     818/883
(92 %)
16 diff
(98.2 %id)
CD051213 embryonic trophoblasts, made from WA01 stemcells .n 2453 to 3286 22 to 870 K88E V95A     849/909
(93 %)
25 diff
(97.3 %id)
BE259580 brain, neuroblastoma .n 2455 to 3119 1 to 661 K147T L188W E189R A190R V191W ...     661/715
(92 %)
6 diff
(99.2 %id)
CD049572 embryonic stem cells, WA01, passage 38 .n 2457 to 3325 27 to 895 Q27R E189G     869/897
(96 %)
13 diff
(98.6 %id)
BG772709 testis .n 2457 to 3259 6 to 803 exact     798/804
(99 %)
16 diff
(98.1 %id)
BM557394 amelanotic melanoma, cell line, skin .n 2457 to 3251 1 to 795 exact     795/1076
(73 %)
4 diff
(99.7 %id)
BM043864 carcinoma, cell line, Prostate .n 2458 to 3196 1 to 739 L2C P3R A4R A5R A6S ...     739/740
(99 %)
15 diff
(98.0 %id)
CD048596 embryonic stem cells, WA01, passage 38 .n 2459 to 3341 25 to 917 exact     893/919
(97 %)
26 diff
(97.2 %id)
CD048650 embryonic stem cells, WA01, passage 38 .n 2459 to 3332 23 to 901 A177P     879/904
(97 %)
19 diff
(97.9 %id)
CD049284 embryonic stem cells, WA01, passage 38 .n 2459 to 3328 22 to 897 exact     876/897
(97 %)
21 diff
(97.7 %id)
BI116292 lung, small cell carcinoma .n 2460 to 3162 1 to 704 R127P T128D H129T T131H V132R ...     704/799
(88 %)
8 diff
(99.0 %id)
BU542197 carcinoma, cell line, Prostate .n 2460 to 3284 1 to 835 exact     835/884
(94 %)
15 diff
(98.4 %id)
BE745408 adenocarcinoma cell line, ovary .n 2461 to 3132 1 to 672 L188W E189R A190R V191W G192A ...     672/673
(99 %)
4 diff
(99.5 %id)
BM010741 amelanotic melanoma, cell line, skin .n 2461 to 2990 1 to 531       531/531
(100 %)
3 diff
(99.5 %id)
BM810888 amelanotic melanoma, cell line, skin .n 2461 to 3206 8 to 760 exact     753/1150
(65 %)
10 diff
(99.2 %id)
TI_59385593   .n 2461 to 2990 106 to 636       531/531
(100 %)
3 diff
(99.5 %id)
BM557427 amelanotic melanoma, cell line, skin .n 2462 to 3210 1 to 750 exact     750/1053
(71 %)
10 diff
(99.1 %id)
BM555175 amelanotic melanoma, cell line, skin .n 2462 to 3167 1 to 709 exact     709/1096
(64 %)
9 diff
(99.2 %id)
BQ652824 hepatocellular carcinoma, cell line, Liver .n 2462 to 3259 1 to 804 V196G     804/1005
(80 %)
26 diff
(97.5 %id)
BM562706 astrocytoma grade IV, cell line, brain .n 2463 to 3340 1 to 888 exact     888/1071
(82 %)
31 diff
(97.2 %id)
BE267232 lung, small cell carcinoma .n 2466 to 3293 1 to 823 L2C P3G A4G A6R R7P ... AAA   823/907
(90 %)
34 diff
(96.3 %id)
BE312034 brain, neuroblastoma .n 2467 to 3148 1 to 674 E148D I149N K150Q N151E Y152L ...     674/674
(100 %)
10 diff
(98.6 %id)
BE257233 eye, retinoblastoma .n 2467 to 3166 1 to 693 C13A L16F R17G A18P A19L ...     693/763
(90 %)
15 diff
(98.1 %id)
BE252879 eye, retinoblastoma .n 2467 to 2979 1 to 516       516/517
(99 %)
3 diff
(99.5 %id)
BC007497 Muscle, rhabdomyosarcoma .n 2470 to 3356 1 to 887 exact available from MGC, AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 887/887
(100 %)
1 diff
(99.9 %id)
CD049387 embryonic stem cells, WA01, passage 38 .n 2472 to 3251 24 to 814 exact AAA   791/932
(84 %)
25 diff
(97.4 %id)
U25041 tonsil .n 2472 to 3356 7 to 889 L134R Q154K G155A I156S N157T ... AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 883/889
(99 %)
10 diff
(98.9 %id)
BG831837 epithelioid carcinoma cell line, Pancreas .n 2475 to 3208 1 to 734 S105P     734/734
(100 %)
4 diff
(99.5 %id)
BE728827 melanotic melanoma, skin .n 2477 to 3328 1 to 840 H42I Q43R R44G C45V E46R ...     840/924
(90 %)
25 diff
(97.3 %id)
BE728313 melanotic melanoma, skin .n 2480 to 3197 1 to 717 V143C K144E L145A I146D K147Q ...     717/717
(100 %)
14 diff
(98.1 %id)
BQ054863 lymph, lymphoma, cell line .n 2480 to 3180 1 to 705 A177P     705/1116
(63 %)
14 diff
(98.8 %id)
EF036488   .n 2482 to 2734 1 to 253       253/253
(100 %)
0 diff
(100 %id)
BE260457 brain, neuroblastoma .n 2482 to 3268 1 to 774 A6L R7A L9C W10G P12L ...     774/855
(90 %)
26 diff
(97.0 %id)
CV026666 mixed .n 2484 to 3082 1 to 599 exact     599/649
(92 %)
2 diff
(99.7 %id)
BE267327 lung, small cell carcinoma .n 2487 to 3193 1 to 701       701/742
(94 %)
20 diff
(97.4 %id)
TI_151758080   .n 2489 to 3234 36 to 780     Submitted on the opposite strand 745/806
(92 %)
13 diff
(98.4 %id)
BU855273 ovary, teratocarcinoma, cell line .n 2490 to 3305 1 to 825       825/852
(96 %)
12 diff
(98.6 %id)
BE263607 lung, small cell carcinoma .n 2492 to 3097 1 to 604       604/605
(99 %)
3 diff
(99.6 %id)
BF433010 carcinoid, lung .n 2492 to 3095 1 to 604     Submitted on the opposite strand 604/604
(100 %)
1 diff
(99.9 %id)
AI334194 lung .n 2493 to 3044 1 to 552     Submitted on the opposite strand 552/552
(100 %)
0 diff
(100 %id)
AI571774 anaplastic oligodendroglioma, brain .n 2493 to 3058 1 to 567     Submitted on the opposite strand 567/567
(100 %)
1 diff
(99.9 %id)
AI924635 lung, squamous cell carcinoma, poorlydifferentiated (4 pooled tumors, including primary andmetastatic) .n 2493 to 3077 1 to 585     Submitted on the opposite strand 585/585
(100 %)
1 diff
(99.9 %id)
AW009230 colon .n 2493 to 3058 1 to 566     Submitted on the opposite strand 566/567
(99 %)
1 diff
(99.9 %id)
BE044511 pooled .n 2493 to 3077 1 to 585     Submitted on the opposite strand 585/585
(100 %)
1 diff
(99.9 %id)
BE796335 lung, small cell carcinoma .n 2493 to 3206 1 to 714       714/716
(99 %)
6 diff
(99.2 %id)
TI_151706284   .n 2493 to 3233 60 to 796     Submitted on the opposite strand 737/823
(89 %)
17 diff
(98.0 %id)
BF434077 fibrotheoma, ovary .n 2503 to 3027 1 to 526     Submitted on the opposite strand 526/526
(100 %)
1 diff
(99.9 %id)
AI452928 pooled .n 2511 to 3035 1 to 525     Submitted on the opposite strand 525/525
(100 %)
4 diff
(99.3 %id)
BF108717 pooled .n 2534 to 3046 1 to 513     Submitted on the opposite strand 513/514
(99 %)
4 diff
(99.3 %id)
BF061654 fibrotheoma, ovary .n 2545 to 3077 1 to 533     Submitted on the opposite strand 533/533
(100 %)
1 diff
(99.9 %id)
BU579410 insulinoma, Pancreas .n 2551 to 2859 1 to 309   fully sequenced, Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 309/309
(100 %)
3 diff
(99.1 %id)
TI_149286407   .n 2556 to 3356 898 to 109   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 790/1102
(71 %)
18 diff
(98.4 %id)
BQ431648 leiomyosarcoma, uterus .n 2557 to 3358 833 to 24   AAA Submitted on the opposite strand 810/856
(94 %)
17 diff
(98.1 %id)
BQ719589 sympathetic trunk .n 2557 to 3351 852 to 52   AAA Submitted on the opposite strand 801/917
(87 %)
34 diff
(96.3 %id)
TI_151759591   .n 2558 to 3358 887 to 91   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 797/935
(85 %)
8 diff
(99.2 %id)
TI_149296006   .n 2563 to 3356 877 to 94       784/1012
(77 %)
12 diff
(98.9 %id)
TI_149285523   .n 2573 to 3356 914 to 133   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 782/1061
(73 %)
18 diff
(98.4 %id)
BM728111 eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid .n 2582 to 3308 728 to 1     Submitted on the opposite strand 728/728
(100 %)
4 diff
(99.5 %id)
BF338631 brain, glioblastoma with EGFR amplification .n 2584 to 3359 1 to 766   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 766/766
(100 %)
17 diff
(97.8 %id)
CX753275 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .n 2597 to 3356 775 to 22   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 754/792
(95 %)
11 diff
(98.7 %id)
BG030849 breast, mammary adenocarcinoma, cell line .n 2599 to 3339 1 to 742   AAA   742/757
(98 %)
8 diff
(99.0 %id)
BF220241 muscle, rhabdomyosarcoma .n 2609 to 3314 702 to 1       702/702
(100 %)
8 diff
(98.9 %id)
AF105278   .n 2618 to 3356 1 to 738   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 738/738
(100 %)
6 diff
(99.2 %id)
BG686107 B-cells, primary B-cells from tonsils (cell line) .n 2623 to 3350 1 to 729       729/729
(100 %)
2 diff
(99.8 %id)
CA307884 Alveolar Macrophage, lung .n 2649 to 3356 726 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 708/708
(100 %)
1 diff
(99.9 %id)
CN270379 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .n 2657 to 3224 1 to 568       568/568
(100 %)
1 diff
(99.9 %id)
BP419781 small intestine .n 2662 to 3198 1 to 538     Submitted on the opposite strand 538/538
(100 %)
4 diff
(99.3 %id)
BM797033 Ascites, stomach .n 2697 to 3126 1 to 430       430/430
(100 %)
0 diff
(100 %id)
BU684064 lung, Primary Lung Cystic Fibrosis EpithelialCells .n 2703 to 3356 674 to 21       654/674
(97 %)
0 diff
(100 %id)
BG576319 breast, mammary adenocarcinoma, cell line .n 2712 to 3309 1 to 598       598/598
(100 %)
1 diff
(99.9 %id)
BQ773890 Chondrosarcoma Grade II, Left Pelvis .n 2713 to 3360 666 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 648/648
(100 %)
1 diff
(99.9 %id)
BU737870 eye, lens .n 2714 to 3365 670 to 19   tiling clone, fully sequenced, AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 652/652
(100 %)
0 diff
(100 %id)
AI807809 pooled .n 2715 to 3077 1 to 363     Submitted on the opposite strand 363/363
(100 %)
0 diff
(100 %id)
CF541409 lung .n 2715 to 3358 661 to 17   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 645/645
(100 %)
2 diff
(99.7 %id)
CA424282 Bone, Enchondroma cell line .n 2741 to 3365 645 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 627/627
(100 %)
2 diff
(99.7 %id)
TI_158432904   .n 2745 to 3361 711 to 94   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 618/859
(71 %)
10 diff
(98.9 %id)
CA308952 Alveolar Macrophage, lung .n 2748 to 3356 628 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 610/610
(100 %)
1 diff
(99.9 %id)
CA503230 Human Lung Epithelial cells, lung .n 2749 to 3356 626 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 608/608
(100 %)
0 diff
(100 %id)
CA310089 Bone, Enchondroma cell line .n 2759 to 3365 625 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 607/609
(99 %)
1 diff
(99.9 %id)
BM792515 Ascites, stomach .n 2762 to 3360 1 to 599       599/603
(99 %)
2 diff
(99.7 %id)
CA308525 Alveolar Macrophage, lung .n 2763 to 3356 612 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 594/594
(100 %)
0 diff
(100 %id)
BM043635 carcinoma, cell line, Prostate .n 2767 to 3356 1 to 590   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 590/590
(100 %)
1 diff
(99.9 %id)
AW009148 colon .n 2775 to 3357 583 to 1       583/583
(100 %)
0 diff
(100 %id)
EC577385 Prostate .n 2781 to 2881 1 to 101       101/101
(100 %)
0 diff
(100 %id)
AI015536 Kidney .n 2784 to 3356 573 to 1       573/573
(100 %)
3 diff
(99.5 %id)
BM811363 amelanotic melanoma, cell line, skin .n 2791 to 3356 1 to 566       566/566
(100 %)
1 diff
(99.9 %id)
AW157625 brain, frontal lobe .n 2798 to 3333 536 to 1   fully sequenced,   536/536
(100 %)
4 diff
(99.3 %id)
BG492021 amelanotic melanoma, cell line, skin .n 2798 to 3310 514 to 1   fully sequenced,   514/514
(100 %)
4 diff
(99.3 %id)
BG775710 carcinoma, cell line, Prostate .n 2798 to 3304 508 to 1   fully sequenced,   508/508
(100 %)
6 diff
(98.9 %id)
BI084780 epidermoid carcinoma, cell line, salivary gland .n 2798 to 3308 512 to 2   fully sequenced,   511/512
(99 %)
0 diff
(100 %id)
BI084894 epidermoid carcinoma, cell line, salivary gland .n 2798 to 3314 515 to 1   fully sequenced,   515/515
(100 %)
4 diff
(99.3 %id)
BU074120 insulinoma, Pancreas .n 2798 to 3356 575 to 18   fully sequenced, AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 558/558
(100 %)
1 diff
(99.9 %id)
EC489401 Prostate .n 2818 to 2925 1 to 108       108/108
(100 %)
0 diff
(100 %id)
AJ710524 heart .n 2824 to 3354 531 to 1     Submitted on the opposite strand 531/531
(100 %)
0 diff
(100 %id)
BM971991 lung .n 2824 to 3356 551 to 19   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 533/533
(100 %)
0 diff
(100 %id)
AW247183 lung, small cell carcinoma .n 2826 to 3358 543 to 11   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 533/533
(100 %)
0 diff
(100 %id)
CF528686 placenta .n 2833 to 3361 546 to 18   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 529/529
(100 %)
2 diff
(99.7 %id)
AI127960 uterus .n 2862 to 3358 497 to 1       497/497
(100 %)
0 diff
(100 %id)
BF975560 B-cells, primary B-cells from tonsils (cell line) .n 2864 to 3356 1 to 493   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 493/493
(100 %)
0 diff
(100 %id)
AA852058 brain .n 2911 to 3356 1 to 446       446/446
(100 %)
0 diff
(100 %id)
AJ711155 heart .n 2921 to 3239 1 to 319       319/319
(100 %)
0 diff
(100 %id)
CN270375 embryonic stem cells, cell lines H1, H7, andH9 .n 2960 to 3356 442 to 46   AAA Submitted on the opposite strand 397/397
(100 %)
0 diff
(100 %id)
TI_59386703   .n 2967 to 3358 111 to 502   AAA Possibly primed on the genome, locally A rich (16/16 A in genome downstream of last aligned base) 392/392
(100 %)
0 diff
(100 %id)
AW001566 colon, colonic mucosa from 3 patients with Crohn'sdisease .n 2968 to 3360 393 to 1       393/393
(100 %)
0 diff
(100 %id)
AI199487 anaplastic oligodendroglioma, brain .n 3007 to 3357 351 to 1       351/351
(100 %)
0 diff
(100 %id)
AI688672 colon .n 3023 to 3358 336 to 1       336/336
(100 %)
0 diff
(100 %id)
AI659038 Prostate .n 3034 to 3313 280 to 1       280/280
(100 %)
0 diff
(100 %id)
CA488587   .o 1 to 853 1 to 857 T7P C8A F9S C10V F11S ... tiling clone,   857/914
(93 %)
15 diff
(98.4 %id)
DA263747 caudate nucleus .p 1 to 571 2 to 572   tiling clone, capped   571/571
(100 %)
0 diff
(100 %id)
DB148852 thymus .p 398 to 921 2 to 525   tiling clone, capped   524/524
(100 %)
0 diff
(100 %id)
AA586792 colon, colon tumor RER+ .p 635 to 1053 1 to 417   tiling clone, Submitted on the opposite strand 417/417
(100 %)
2 diff
(99.6 %id)
CR976023 T-Lymphocytes .q 1 to 688 1 to 688 S24X Q25X Q37X Q44X K63X ... tiling clone,   688/690
(99 %)
2 diff
(99.8 %id)
CX755715 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .q 19 to 710 1 to 743     Submitted on the opposite strand 636/824
(77 %)
71 diff
(91.4 %id)
AK021483 whole embryo, mainly head .r-u 1 to 1810 2 to 1811 exact tiling clone, available from FLJ,   1811/1811
(100 %)
3 diff
(99.9 %id)
AU117253 whole embryo, mainly head .r-u 1 to 710 2 to 710   capped   709/709
(100 %)
6 diff
(99.2 %id)
CN360024 embryonic stem cells, DMSO-treated H9 cellline .r-u 75 to 840 1 to 770       770/809
(95 %)
10 diff
(98.8 %id)
AU144143 whole embryo, mainly head .r-u 1210 to 1810 601 to 1 exact     601/605
(99 %)
12 diff
(98.1 %id)
BF815090 colon_ins .s 1 to 227 235 to 12   tiling clone, Submitted on the opposite strand 224/265
(84 %)
2 diff
(99.3 %id)
DA654784   .s 42 to 582 8 to 548 exact tiling clone, capped   541/541
(100 %)
0 diff
(100 %id)
BQ712544 Spleen .t-u 1 to 784 13 to 796 exact tiling clone,   784/953
(82 %)
10 diff
(99.0 %id)
AA341240 Kidney .t-u 444 to 670 1 to 228       228/228
(100 %)
2 diff
(99.2 %id)
BG011695 placenta_normal .t-u 461 to 847 23 to 408   tiling clone,   386/412
(93 %)
9 diff
(97.9 %id)
CK431149 eye, lacrimal gland .u 1 to 595 1 to 595 exact tiling clone,   595/595
(100 %)
0 diff
(100 %id)
AA013278 eye, retina .u 562 to 696 33 to 169   tiling clone,   137/169
(81 %)
6 diff
(96.5 %id)
AA013251 eye, retina .u 1963 to 2322 365 to 1   tiling clone,   365/387
(94 %)
10 diff
(97.5 %id)
CN402908 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .va 1 to 549 1 to 549 exact tiling clone,   549/551
(99 %)
3 diff
(99.5 %id)
CA395103 eye, RPE/choroid .vb 1 to 346 1 to 350 C2F P16L S43P L107R Y108S ... tiling clone,   346/350
(98 %)
4 diff
(98.9 %id)
BG954905 colon .vc-u 1 to 327 333 to 8 H79P K107N H108T Q109X tiling clone,   326/343
(95 %)
0 diff
(100 %id)
CN304705 embryonic stem cells, cell lines H1, H7, andH9 .vd 1 to 286 1 to 286 exact tiling clone,   286/286
(100 %)
0 diff
(100 %id)
TI_44166418   .ve 1 to 726 91 to 824 T2A R3G G60W S61V A62G ... tiling clone,   682/825
(82 %)
21 diff
(97.5 %id)
BI027702 marrow .vf-u 1 to 481 494 to 13 H49P tiling clone,   482/494
(97 %)
0 diff
(100 %id)
199 other accessions, mainly redundant or of lesser quality, also belong to this gene but are not reported.
? Gene Summary Gene on genome mRNA:.a, .b, .c, .d, .e, .f, .g, .h-u, .i, .j, .k, .l, .m, .n, .o, .p, .q, .r-u, .s, .t-u, .u, .va, .vb, .vc-u, .vd, .ve, .vf-u Alternative mRNAs features, proteins, introns, exons, sequences Expression Tissue Function, regulation, related genes DCI